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ABSTRACT 
Carbohydrates are ubiquitous in nature and provide the function of protection and 
recognition in many biological systems. Therefore, the efficient synthesis of carbohydrate-based 
compounds is of considerable interest for both research and commercial purposes. However, 
unlike DNA and protein, successful synthesis of glycan is still challenging, due to the large 
number of sugar nucleotides and the several different linkage and conformation. Therefore, to 
tackle the challenge of glycosynthesis, chemists are increasingly turning their attention towards 
enzymes, which are exquisitely adapted to the intricacy of these biomolecules. In this 
dissertation, we will focus on practical biosynthesis of glycome such as UDP-GlcA and UDP-
GalA, HMOcomics, O-Polysaccharides. 
Chapter 1 provides a general introduction of function of glycosylation of protein and 
glycan synthetic approaches.  
Chapter 2 describes that innovative approach of biosynthesis of UDP-GlcA and UDP-
GalA by utilizing salvage pathway. UDP-HexA is active form of monosaccharide for further 
glycosylation which occurs in the biosynthesis of numerous cell components. Limited 
availability of these sugar nucleotides has been hindering the development of facile synthesis of 
bioactive glycans. In this study, we have developed an efficient and facile one-pot multi-enzyme 
method to harvest hundreds milligram of UDP-GlcA and UDP-GalA.  
In Chapter 3, Human milk sugar library synthesis is the footstone for future 
manufacturing specific human milk sugar macro array which can be used for screening blood 
and virus. A tremendous human milk sugar library is the foundation for application of macro-
array in multiple research area. we accomplished a work of chemoenzymatic synthesize 31 
HMOs based on 3 chemically synthesized core structures. A more comprehensive 100 HMOs 
library by 7 robust glycosyltransferases have been accomplished for printing array to screen 
virus and bacteria. 
In Chapter 4, chemoenzymatic synthesis of O-antigen from P. aeruginosa serotype O11 
was achieved by two glycotransferases WbjE and WbjA. The bacterial cell surface is decorated 
with polysaccharides whose structures show remarkable diversity. These polysaccharides play 
critical role of interaction between Host and bacterium. Many are important virulence factors, 
adhesion mediators, or immunomodulators. Successful reconstitution of pure homogenous repeat 
unit of PS can facilitate development of multivalence bacterial vaccine.  
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1 INTRODUCTION  
1.1 Function of glycan and glycoconjugate  
Glycan and glycoconjugates are the fundamental mediator in nature which play pivotal 
roles in signaling, cell-cell interaction, cell differentiation, cell proliferation, immunological 
responses. 1 The chemical structure diversity and complexity of glycans underlie their functional 
variety. The function exerted are also very diverse containing: (1) organizational and stability 
role, (2) protective and barrier functions, (3) provision of specific receptors for microorgamisms  
 
 
Figure 1.1 glycans mediate multiple mechanisms of cellular interaction. 
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Toxin, virus, antibodies, enzymes to attack, shield and lure, (4) modulating protein 
functions, (5) intra and inter cellular trafficking, (6) mediator of cell-cell and cell-matrix 
interactions. 2(Figure 1.1) 
Glycosylation is a most important post-translational modification of protein that increase 
protein diversity and function. In general glycosylation is defined as the addition of one or more 
sugar residues to a protein or lipid to convey additional information, structure or function. There 
are five types of glycosylation in mammalian cell: (1) N-glycosylation in which glycan is 
attached to nitrogen of asparagine (Asn), (2) O-Glycosylation in which glycan is attached to 
hydroxyl oxygen of serine (Ser) or threonine (Thr), (3) Phosphoserine glycosylation in which 
sugar is linked to the phosphate of a phosphoserine, (4) C-linked glycosylation in which glycan 
is attached to a carbon of a tryptophan side chain, (5) glypiation (glycosylphosphatidylinositol-
anchored proteins). 3 (Figure 1.2) 
 
 
Figure 1.2 Different types of glycosylated proteins 
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Unlike DNA, composed of adenine(A), cytosine (C), guanine (G), thymine (T), and 
peptide or protein, composed of 20 amino acid, glycan can be either linear or branched which is 
controlled by certain number of glycotransferases which belong to intrinsic biosynthesis 
pathway. 4 these specific glycotransferases can transfer corresponding monosaccharide to 
another one by forming glycosidic bond. Every monosaccharide has several hydroxyl groups 
which can link to hydroxyl group of another monosaccharide’s anomeric carbon by either α or β 
configuration. There are more than ten types of monosaccharide existing in nature. Based on 
above several characters, numerous sequence and structure of glycans were found in bacteria, 
mammalian cell and organism. The diversity of glycan enables it to carry more complicate signal 
information and convey it through specific interaction. 
1.2 Preparation of glycome 
Glycome is a whole collection of different form of carbohydrate existing in cell, tissue, 
organism. 5 Successful preparation of such big carbohydrate collection will be tremendous 
benefit to glycoscience. Until now the lack of structure defined glycan as standard has impeded 
the interpretation of oligosaccharides or glycan function and their mechanism behind scene. 6-7 
To address this fundamental problem, isolation and synthesis are two major direction. Each one 
has their own advantages and disadvantages. Currently human milk oligosaccharides isolated 
from natural human milk, glycans from glycolipid and glycoprotein, and polysaccharides from 
bacteria are some examples by isolation approach. 8-11 although glycan isolated from natural 
product is reliable large scale of source for industry application, most of them are mixtures which 
need further separation. 12 Especially when some isolated glycans are same molecular weight but 
different structure, separation is very challenging.  In contrast synthesized glycan by either 
chemical or enzymatic approach are structurally defined glycan which are widely utilized in 
4 
 
biological and biomedical studies.13-14 Chemical synthesis are mutil-steps process, time 
consuming, low yield and strict reaction conditions. 15 those aspects determine that chemical 
synthesis mostly fits small molecular synthesis. Oligosaccharides over 1000 KDa prefer 
enzymatic synthesis. 16 The key factor of enzymatic synthesis is robust glycostransferases (GT) 
from mammalian or bacteria and corresponding sugar nucleotides. 17 (Figure 1.3) 
 
Figure 1.3 Common monosaccharides and corresponding sugar nucleotides 
 
Glycotransferase catalyzed enzymatic and chemoenzymatic synthesis are highly specific 
and regio and stereo control. Recently Dr. Xi Chen and her coworkers employ a new strategy 
called One-pot multienzyme (OPME) system to boost yield of carbohydrate synthesis. In OPME, 
glycotransferases for forming specific glycosylic bond and enzymes involved in biosynthetic 
pathway of corresponding sugar nucleotides are combined into one reaction system to drive 
reaction forward and avoid tedious separation. 17 
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1.3 Outline of the work in this dissertation 
The work in this dissertation mainly focuses on biosynthesizing sugar nucleotides, 
oligosaccharides from human milk and O-antigen from bacteria. In chapter 2, we biochemically 
characterized two UDP-sugar pyrophosphorylases from Arabidopsis thaliana (AtUSP) and 
Bifidobacterium infantis ATCC15697 (BiUSP). Both enzymes showed significant 
pyrophosphorylation activities towards GlcA-1-phosphate, and AtUSP also exhibited 
comparable activity towards GalA-1-phosphate. By combing with monosaccharide-1-phosphate 
kinases, we have developed an efficient and facile one-pot three-enzyme approach to quickly 
obtain hundreds mg of UDP-GlcA and UDP-GalA. In chapter 3, an efficient chemoenzymatic 
strategy, namely Core Synthesis/Enzymatic Extension (CSEE), for rapid production of diverse 
HMOs was reported. 3 core structures were chemically synthesized. Each of these core structures 
was then extended to up to 11 HMOs by 4 robust glycosyltransferases. A library of 31 HMOs 
were chemoenzymatically synthesized and characterized by MS and NMR. CSEE indeed 
provides a practical approach to harvest structurally defined HMOs for various applications.  In 
chapter 4, we have successfully reconstituted pure homogenous O-repeat unit of P. aeruginosa 
O11, which will facilitate development of multi-valence bacterial vaccine towards opportunistic 
P. Aeruginosa infection in hospital. 
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2 ONE POT ENZYMATIC SYNTHESIS OF UDP-GLCA AND UDP-GALA 
2.1 Introduction 
Hexuronic acids (HexAs), a class of sugar acids with both carbonyl and carboxylic acid 
functional groups, are the oxidation products of the corresponding monosaccharides. Glucuronic 
acid (GlcA) is one of the most commonly found HexAs in the plant and animal kingdoms.18 It is 
also prevalent in carbohydrate chains of proteoglycans.19 Galacturonic acid (GalA) is a major 
sugar residue of plant pectic polysaccharides and a minor component of certain plant 
arabinogalactan proteins.20 GalA is also found in various cell surface polysaccharides of different 
gram-negative bacteria,21-22 as well as capsular polysaccharide of the gram-positive human 
pathogens, such as type I Streptococcus pneumonae.23  
Because of the biological significance and structure complexity, glycans containing 
HexAs have attracted considerable attention in past decades.24-26 One of the major bottlenecks in 
basic research and application of these components is the limited and cost-effective availability 
of uridine 5’-diphosphate glucuronic acid (UDP-GlcA) and uridine 5’-diphosphate galacturonic 
acid (UDP-GalA), the active forms of corresponding monosaccharides. UDP-GlcA and UDP-
GalA are essential glycosyl donors for glycosyltransferases in the biosynthesis of various cell 
components including glycosaminoglycans, some N- and O-linked glycans, glycosphingolipids, 
lectins, etc.27-28 Recently, several chemical or coupled enzymatic approaches have been 
developed for the synthesis of UDP-GlcA and UDP-GalA.29-30 However, low yield, tedious steps 
and strict condition requirements have restricted the application of these approaches in large 
scale sugar nucleotide preparation.31 Therefore, a simple, cost-effective and efficient approach 




Enzymatic synthesis, which mimics the biosynthesis pathway, is considered more 
attractive with advantages of high conversion rate and mild reaction conditions. As shown in 
Figure 1, the de novo biosynthesis of UDP-GlcA initiates from glucose-6-phosphate (Glc-6-P), 
an intermediate of the glycolytic pathway. Three enzymatic catalyzed steps were involved, 
including the equilibrium conversion of Glc-6-P and Glc-1-P, the pyrophosphorylation step to 
yield UDP-Glc, and the oxidoreduction step catalyzed by UDP-Glc 6’-oxidoreductase. The 
complication of the pathway, the similarities between the final product and intermediates, as well 
as the consuming of expensive NAD+ or NADP+ have highly limited the application of such a 
pathway in large scale UDP-GlcA preparation. The de novo biosynthetic pathway of UDP-GalA 
is even more complicated (Fig. 1).  
In contrast, salvage biosynthetic pathways of sugar nucleotides, usually involving only 
two reactions (sugar-1-phosphate kinase catalyzed formation of sugar-1-P from monosaccharide 
and ATP, and NDP-sugar pyrophosphorylase catalyzed formation of NDP-sugar from sugar -1-P 
and NTP) were found much more practical in large scale synthesis of sugar nucleotides. Using 
recombinant enzymes from salvage pathways, we have successfully developed efficient 
approaches for 100 mg scale synthesis of UDP-Gal, UDP-GlcNAc, UDP-GalNAc, GDP-Fuc, 
GDP-Man and derivatives.32-39 Recently, a salvage biosynthetic pathway of UDP-GlcA had been 
discovered in Arabidopsis thaliana (Fig. 1).40 In such a pathway, GlcA is first catalyzed by a 
glucuronokinase (AtGlcAK) to form GlcA-1-P in the presence of ATP and Mg2+. Subsequently, 
a UDP-sugar pyrophosphorylase (AtUSP) catalyzes the conversion of GlcA-1-P into UDP-GlcA 
in the presence of UTP and Mg2+.41-42 A galacturonokinase (AtGalKA) was also found in A. 





Figure 2.1 De novo and salvage biosynthetic pathway of UDP-GlcA and UDP-GalA 
A), Glucuronokinase (GlcAK); B) UDP-sugar pyrophosphorylase (USP); C) UDP-glucose 6-
dehydrogenase; D) Phosphoglucomutase; E) UTP: glucose-1-phosphate 
uridylyltransferase (GalU); F) UDP-Glc 40-epimerase (GalE); G) UDP-galactose 6-
dehydrogenase; H) galacturonokinase (GalAK); I) UDP- galacturonate 
pyrophosphorylase. 
 
In this study, we cloned and characterized a UDP-sugar pyrophosphorylase from 
Bifidobacterium infantis ATCC15697 (BiUSP) which exhibited significant activity towards 
GlcA-1-P. In addition, we codon optimized the gene encoding AtUSP, and performed 
heterogeneous overexpression. AtUSP showed significant activities towards both GlcA-1-P and 
GalA-1-P. Furthermore, substrate specificity study exhibited that both USPs were promiscuous 
towards a panel of sugar-1-phosphates. Finally, by combing sugar-1-P kinases with USPs as well 
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as pyrophosphatase, we developed an efficient one-pot three-enzyme approach to prepare 
hundreds of milligrams of UDP-GlcA and UDP-GalA. 
 
2.2 Results and discussion 
 
Genes encoding AtGlcAK and AtUSP from A. thaliana were codon optimized (see DNA 
sequences in supporting information) and synthesized to achieve better heterologous 
expression in E. coli. The synthesized genes were cloned into pQE80L, a tightly controlled E. 
coli protein expression vector with a T5 promoter. Given that inductions were performed at a low 
temperature (16 °C) and with a low concentration of IPTG (0.2 mM), AtGlcAK and AtUSP were 
expressed almost entirely in soluble form. As shown in Figure 2, after one-step Ni-NTA affinity 
chromatography, both enzymes with N-terminal His6-tag were purified to 90% with high yields 
(90 mg for AtGlcAK, 42 mg AtUSP per L of LB cultures). The apparent molecular weights of 
the enzymes on SDS-PAGE (Fig. 2, Lane 1 & 2) are consistent with theoretical values. 
A bacterial UDP-sugar pyrophosphorylase gene, Blon_1169, was cloned from B. infantis 
ATCC 15697. The enzyme (BiUSP) encoded by this gene is highly identical (98%) to a 
previously reported UDP-sugar pyrophosphorylase, BLUSP.43 BiUSP was expressed and 
purified with a C-terminal His6-tag followed the abovementioned methods. The yield of pure 
BiUSP from 1 L of cultures is 43 mg. An approximate molecular weight of 60 KDa was 




2.2.1 Gene cloning, expression, and purification of AtGlcAK, AtUSP and BiUSP 
 
Figure 2.2SDS-PAGE analysis of purified enzymes 
 
Capillary Electrophoresis (CE) was used to analyze the formation of UDP-sugars. Retention 
times of 21.7, 18.2, 16.6 min were observed on CE profiles for UTP, UDP-GlcA and UDP-GalA 
standards (Fig 3A, B & C), respectively. The results show that BiUSP could catalyze the 
formation of UDP-GlcA from GlcA-1-P and UTP efficiently (Fig. 3D), whereas the formation of 
UDP-GalA was not clearly observed (CE profile not shown), indicating that the C-4 hydroxyl 
group may be necessary for BiUSP recognition. This is opposite with results yielded form 
activity assays towards Glc-1-P and Gal-1-P, where both substrates can be well accepted (Table 
2). One possible explanation could be the bulky carboxylic acid group on C-6 position altered the 





2.2.2 Pyrophosphorylase activities of AtUSP and BiUSP 
 
 
Figure 2.3 CE Profiles of compound standards, and BiUSP/AtUSP catalyzed reactions. 
(A) 0.5 mM UTP; (B) 0.5 mM UDP-GlcA; (C) 0.5 mM of UDP-GalA; (D) BiUSP 
catalyzed generation of UDP-GlcA; (E) AtUSP catalyzed generation of UDP-GlcA; (F) AtUSP 
catalyzed generation of UDP-GalA. For each reaction, 0.8 mM sugar-1-P, 1 mM UTP, and 1 mg 
enzyme was used in a total 50 mL system, reactions were proceeded at 37 _C for 20 min. UTP 
has a retention time of 21.7±0.1 min, UDP-GlcA has a retention time of 18.2±0.1 min, and UDP-
GalA has a retention time of 16.6±0.1 min. 
 
On the other hand, AtUSP could efficiently (68% and 65% towards GlcA-1-P and GalA-1-
P) catalyze the formation of both UDP-GlcA and UDP-GalA (Fig. 3E & F). The activity of 
BiUSP and AtUSP towards GlcA-1-P are comparable (Fig. 3D & E). It is worth to note that 
AtUSP can be stored for up to 6 months at -20 °C without significant activity loss, whereas 
BiUSP showed dramatically activity decrease after 6 months storage under the same condition.  
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Freshly prepared AtUSP or BiUSP was applied in time course experiment and kinetics 
studies. As shown in Figure 4, time course results imply that for AtUSP, the formation rate of 
UDP-GalA is slightly lower than that of UDP-GlcA. In kinetics studies, to ensure initial reaction 
rates, enzyme dilutions were selected so that less than 15% of substrate conversion was achieved 
within 5 min for each reaction. Kinetic parameters were calculated according to Lineweaver–
Burk equation (Table 1). The Km value of AtUSP towards GlcA-1-P and GalA-1-P are 2.36 × 
10-3 M and 5.50 × 10-3 M, indicates that AtUSP has a higher affinity for GlcA-1-P that GalA-
1-P. The kcat/Km values of AtUSP towards GlcA-1-P is 1.8 times as that of GalA-1-P, implies that 
AtUSP is more efficient for the pyrophosphorylation of GlcA-1-P. The kcat/Km values of AtUSP 
(4.66 × 103 s-1 M-1) and BiUSP (4.72 × 103 s-1 M-1) towards GlcA-1-P are similar, indicating 
they are equally efficient in the synthesis of UDP-GlcA. The kinetics of reverse reactions 
(hydrolysis of UDP-GlcA and UDP-GalA) (Table 1) revealed that AtUSP and BiUSP are 
equally active towards UDP-GlcA, whereas only AtUSP can catalyze the hydrolysis of UDP-
GalA. Such results are consistent with that of forward reactions (formation of UPD-GlcA and 
UDP-GalA).  
Table 2.1 Kinetic parameters of AtUSP and BiUSP towards GlcA-1-P, GalA-1-P, UDP-












AtUSP     
GlcA-1-P 2.36×10-3 3.63×10-4 1
1.0 
4.66×103 
GalA-1-P 5.50×10-3 4.45×10-4 1
3.5 
2.45×103 
UDP-GlcA 2.65×10-3 4.06×10-4 1
2.3 
4.64×103 
UDP-GalA 4.96×10-3 4.59×10-4 1
3.9 
2.80×103 
BiUSP     
GlcA-1-P 1.76×10-3 3.38×10-4 8
.30 
4.72×103 
GalA-1-P         -        -    
- 
       - 
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UDP-GlcA 2.02×10-3 3.71×10-4 9
.12 
4.51×103 
UDP-GalA         -        -    
- 
       - 
 
2.2.3 Substrate specificity study of AtUSP and BiUSP towards sugar-1-phosphates 
It was previously reported that AtUSP possessed relaxed substrate specificity towards 
sugar-1-phosphate. For example, it could well accept Gal-1-P, Glc-1-P, 4-deoxy-4-azido-Gal-1-
P, D-Fuc-1-P, L-Ara-1-P, and Xyl-1-P.38, 41-42 To further investigate the substrate specificities of 
AtUSP and BiUSP, the specific activities towards a panel of sugar-1-phosphates were measured. 
Not surprisingly, BiUSP exhibited similar substrate specificity as BLUSP 43 towards sugar-1-
phosphates (Table 2). In addition, both AtUSP and BiUSP showed broad substrate specificities, 
but towards partially different sugar-1-phosphates. For example, AtUSP are highly active 
towards GlcA-1-P, GalA-1-P, Glc-1-P, Gal-1-P, D-Fuc-1-P, 2-deoxy-Glc-1-P, 2-deoxy-Gal-1-P, 
whereas BiUSP are highly active towards GlcA-1-P, Glc-1-P, Gal-1-P, Man-1-P, 2-deoxy-Glc-1-
P, and 2-deoxy-2-amino-Glc-1-P. Such information is of great importance in applying the USPs 
in large scale synthesis of UDP-sugar and derivatives. 
Table 2.2Substrate specificity of AtUSP and BiUSP towards sugar-1-phosphates 
Specific activity of AtUSP towards GlcA-1-P (12.4 mol min-1 mg-1) was set as 100. ND, 
not detected. 
Sugar-1-phosphate Relative activities 
AtUSP BiUSP 
GlcA-1-P 100 91 
GalA-1-P 75.7 ND 
Glc-1-P 130 141 
Gal-1-P 123 136 
GlcNAc-1-P ND ND 
GalNAc-1-P ND ND 
Man-1-P ND 37.2 
Talose-1-P ND 9.65 
D-Fuc-1-P 61.7 15.4 
2-deoxy-Glc-1-P 73.8 82.0 
2-deoxy-Gal-1-P 53.2 ND 
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6-deoxy-6-azido-Gal-1-P 11.6 ND 
2-deoxy-2-amino-Glc-1-P 7.50 41.8 
2-deoxy-2-amino-Gal-1-P ND ND 
 
 
Figure 2.4 Time Course for UDP-GlcA and UDP-GalA reactions 
Reactions contains 1 mM UTP, 40 ng of At USP or BiUSP, and: 1, AtUSP and 0.05 mM 
GlcA-1-P; 2, AtUSP and 0.8 mM GlcA-1-P; 3, AtUSP and 0.05 mM GalA-1-P; 4, AtUSP and 
0.8 mM GalA-1-P; 5, BiUSP and 0.05 mM GlcA-1-P; 6, BiUSP and 0.8 mM GlcA-1-P. 
 
2.2.4 Preparation and characterization of UDP-GlcA and UDP-GalA 
Given the stability and efficiency, AtUSP was chosen for hundreds of milligrams scale 
synthesis of UDP-HexA. As shown in Figure 5, a one-pot three enzyme approach was 
employed. In the case of UDP-GlcA preparation, the monosaccharide GlcA was first converted 
into GlcA-1-P catalyzed by AtGlcAK, the glucuronokinase from A. thaliana.40 The formation of 
UDP-GlcA was then achieved by AtUSP catalyzed reaction in the presence of UTP, and Mg2+. 
Since UDP-sugar pyrophosphorylases catalyzed relations are usually reversible,20 a 
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pyrophosphatase from E. coli (EcPpA) was added to digest the diphosphate byproduct. The same 
as previously proved,37 addition of EcPpA greatly improved the final yield (207 mg pure UDP-
GlcA in a yield of 89%) by driving the reaction forward. The synthesis of UDP-GalA was 
performed following the same route, except that AtGlcAK was substituted by BiGalK, a 
promiscuous galactokinase exhibiting phosphorylation activity towards GalA.44 The total yield 
of UDP-GalA after P2 purification was 70% (162 mg). 
 
 
Figure 2.5 One-pot three-enzyme synthesis of UDP-GlcA and UDP-GalA 
Enzymes used: AtGlcAK: Glucuronokinase from A. thaliana; BiGalK, Galactokinase 
from B. infantis ATCC15697; AtUSP, UDP-sugar pyrophosphorylase from A. thaliana; EcPpA, 
Pyrophosphatase from E. coli. 
 
 
2.2.4.1   Spectroscopic data of Uridine 5’-diphosphate glucuronic acid 





13C NMR Spectrum of UDP-GlcA 
 




HRMS (ESI): Calcd 580.0343 for C15H22N2O18P2; found: 579. 0256 [M-H
+]-; 
1H NMR (400 MHz, D2O): δ 3.51 (t, J = 9.6 Hz, 1 H), 3.57-3.60 (m,1 H), 3.74 (s,1 H), 
3.79 (t, J = 9.6 Hz, 1H), 4.14 (d, J = 10.4 Hz, 1H), 4.20-4.29 (m,2 H), 4.37-4.38 (m,2 H), 5.62 
(dd, J = 2.8 Hz, J = 7.2 Hz,1 H), 5.97-5.99 (m,2 H), 7.95 (d, J = 8.0 Hz, 1 H); 13C NMR (100 
MHz, D2O): δ 58.33, 63.95  (JC-P= 20.4 Hz), 68.65, 70.37 (JC-P= 33.6 Hz), 70.85, 71.58, 72.02, 
72.77, 82.27 (JC-P= 35.6 Hz), 87.27, 94.36 (JC-P= 26.0 Hz), 101.68, 140.56, 150.84, 165.23; 
31P 
NMR (162 MHz, D2O): δ  -12.06, -10.40;  
 
2.2.4.2   Spectroscopic data of Uridine 5’-diphosphate galacturonic acid 









31P NMR Spectrum of UDP-GlcA 
 
HRMS (ESI): Calcd 580.0343 for C15H22N2O18P2; found: 579. 0258 [M-H
+]-; 
1H NMR (400 MHz, D2O): δ 3.83 (d, J = 10.4 Hz, 1 H), 3.98 (dd, J = 3.2 Hz, J = 10.4 Hz,1 
H), 4.17-4.22 (m,2 H), 4.29-4.32 (m,2 H), 4.36-4.37 (m,2 H), 4.53 (s,1 H), 5.68-5.69 (m,1 H), 
5.97-5.99 (m,2 H), 7.96 (d, J = 8.0 Hz, 1 H); 13C NMR (100 MHz, D2O): δ 58.31, 63.91  (JC-P= 
16.0 Hz), 67.50 (JC-P= 29.2 Hz), 68.32, 68.63, 69.57, 71.70, 72.78, 82.28 (JC-P= 35.6 Hz), 87.25, 
94.71 (JC-P= 20.4 Hz), 101.67, 140.57, 150.84, 165.23; 
31P NMR (162 MHz, D2O): δ  -11.90, -





In summary, we have biochemically characterized two highly efficient UDP-sugar 
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pyrophosphorylases (AtUSP and BiUSP) for the purpose of large scale UDP-HexA preparation. 
Genes or expression conditions were optimized to obtain high yields of enzymes (40-90 mg per 
L culture). Both enzymes showed comparable activities towards GlcA-1-P, whereas only AtUSP 
exhibited activity towards GalA-1-P. Specific activity study revealed that both USPs possessed 
broad substrate specificity, but towards partially different sugar-1-phosphates. In addition, we 
have developed a one-pot three-enzyme approach for efficient and rapid preparation of UDP-
GlcA and UDP-GalA starting from inexpensive monosaccharides and nucleotides. Using such an 
approach, 207 and 162 mgs of UDP-GlcA and UDP-GalA were prepared within one week.  
 
2.4 Experimental section 
2.4.1 Materials 
All chemical reagents were purchased from Sigma unless otherwise noted. Ni-NTA agarose 
was purchased from Qiagen. Talose-1-P,37 D-Fucose-1-P,44 2-deoxy-Gal-1-P,44 2-deoxy-Glc-1-P 
37 were prepared as previously described. The preparation of 6-deoxy-6-azido-Gal-1-P will be 
reported subsequently. Codon optimized gene of AtGlcAK, AtUSP were synthesized by 
Genscript (Piscataway, NJ). Genomic DNA of B. infantis ATCC 15697 was purchase from 
ATCC. E. coli DH5α and BL21 (DE3), as well as vector pET22b were purchased from EMD 
Millipore (Bilerica, MA). Vector pQE80Lwas purchased from Qiagen (Germantown, MD). 
BiGalK expression E. coli strain was kept by our group.  
 
2.4.2 Molecular cloning Protein expression and purification 
The glucuronokinase gene (AtGlcAK) and UDP-sugar pyrophosphorylase gene (AtUSP) 
from A. thaliana was codon optimized and synthesized with restriction sites (SacI and HindIII) 
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(see supporting information for optimized DNA sequences). The genes were then cleaved by SalI 
and HindIII, and inserted into pQE80L pretreated with corresponding restriction enzymes. The 
UDP-sugar pyrophosphorylase gene (BiUSP, Blon_1169) from B. infantis was amplified by PCR 
using B. infantis ATCC15697 genomic DNA as templates. Primers used are, Blon_1169F: 
GAGCATATGACCGAAATAAACGATAAGGCC and Blon_1169R: 
TATCTCGAGCACCCAATCGTCCGGTTCGAT. Yielded PCR fragments were digested with 
NdeI and HindIII and subsequently inserted into pET22b pretreated with corresponding enzymes.  
The recombinant plasmids were verified by DNA sequencing and transformed into E. coli BL21 
(DE3) for protein expression. 
E. coli BL21(DE3) cells harboring the above recombinant plasmids were grown in LB 
medium at 37 °C with shaking (20 rpm) till OD600 reached 0.6-0.8, followed by addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM. After 20 h 
induction at 16 °C the cells were harvested by brief centrifuging, and stored at -80 °C until used. 
Protein purification was performed utilizing a Ni-NTA resin (Qiagen) column according to the 
manufacture instructions. The purified proteins were desalted by PD-10 column (GE life science, 
USA) against 50 mM Tris-HCl (pH 8.0) and 20% of glycerol. Enzymes were kept at -20 °C until 
used.  
 
2.4.3 Activity assays of AtUSP and BiUSP towards GlcA-1-P and GalA-1-P 
A 50 L reaction system in 20 mM Tris-HCl (pH 8.0) consisted of 0.8 mM GlcA-1-P or 
GalA-1-P, 1 mM UTP, 2 mM MgCl2, and varying amount of purified AtUSP or BiUSP. 
Reactions were allowed to proceed at 37 °C for 20 min and quenched by the addition of equal 
volumes of cold ethanol. The formation of UDP-HexA and consumption of UTP was analyzed 
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by Capillary Electrophoresis (Beckman Coulter) using the following conditions:  75 m i.d. 
capillary (Beckman Coulter), 25 KV/140 A, 5 s vacuum injection, 50 mM sodium tetraborate 
running buffer, pH 9.4., monitored at 254 nm.  
 
2.4.4 Determination of kinetic parameters 
Kinetic parameters of both AtUSP and BiUSP towards Glc-1-P and Gal-1-P were measured 
in 50 L reactions in 20 mM Tris-HCl (pH 8.0). The reaction mixtures contain varying 
concentrations of GlcA-1-P or GalA-1-P (0.05, 0.1, 0.2, 0.4, 0.6, 0.8 mM), 1 mM UTP, 2 mM 
MgCl2. Reactions were initiated by the addition of 40 ng of AtUSP or BiUSP, performed at 37 
°C for 5 min, and quenched by addition of equal volumes of cold ethanol. The sugar-1-P 
substrate concentrations used in the time course studies were 0.05 and 0.8 mM. The reactions 
were quenched at 0, 2, 5, 10, 15, 30, and 60 min. Analysis were performed by CE as described 
above, and the average value of triplicate assays was employed to generate Line-weaver-Burk 
plot, and Km, Vmax, kcat values were calculated accordingly. Kinetic parameters of AtUSP and 
BiUSP towards UDP-GlcA and UDP-GalA were measured similarly, by replacing GlcA-1-P or 
GalA-1-P into UDP-GlcA or UDP-GalA, and replacing UTP into pyrophosphate.  
 
2.4.5 Substrate specificity of AtUSP and BiUSP towards various sugar-1-phosphate 
The reaction mixtures (50 L total volume) contain 0.8 mM of different sugar-1-phosphates 
(Table 2), 1 mM UTP and 2 mM MgCl2. Reactions were initiated by the addition of varying 
amounts (0.4-40 g, to make sure the reactions convert no more than 25%) of AtUSP or BiUSP, 
performed at 37 °C for 10 min, and quenched by the addition of equal volumes of cold ethanol. 
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Analysis were performed by CE as described above, and the average value of triplicate assays 
was employed to generate specific activities towards each sugar-1-phosphate.  
 
2.4.6 One pot three enzyme synthesis of UDP-GlcA and UDP-GalA 
Preparative-scale synthesis of UDP-GlcA and UDP-GalA were performed in a 20 mL 
reaction system containing 50 mM pH 8.0 Tris-HCl buffer, 20 mM GlcA or GalA, 22 mM ATP, 
22 mM UTP, 20 mM MgCl2, and 0.1 to 2 mg of different enzymes. For the synthesis of UDP-
GlcA, 0.6 mg of AtGlcAK, 0.4 mg of AtUSP, and 0.1 mg of EcPpA37 were employed; for the 
synthesis of UDP-GalA, 2 mg of BiGalK, 0.4 mg of AtUSP, and 0.1 mg of EcPpA were 
employed. The reaction mixtures were incubated at 37 °C for 4 to 12 hours with gentle shaking. 
The generation of UDP-sugars were monitored by TLC (Isopropanol: NH4OH: H2O = 7: 3: 2). 
After 90% of monosaccharides converted into UDP-sugar, reactions were quenched by boiling 
for 5 min, centrifuged to remove precipitants, and concentrated for separation. The separation of 
UDP-sugars from the reaction mixtures were performed by gel filtration (Bio-Gel P2, Bio-Rad), 
fractions containing products were pooled and lyophilized. Digestion of nucleotides by alkaline 
phosphatase and further P2 purification were applied to achieve minimum 95% purity. The final 
products were lyophilized and characterized by HR-MS and NMR. 
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3 CHEMOENZYMATIC SYNTHESIS OF A LIBRARY OF HUMAN MILK 
OLIGOSACCHARIDES 
3.1 Introduction 
    Human milk, as the sole dietary source, contains all the necessary nutrients for the infant 
to thrive in the first few months. More importantly, human milk can also provide ingredients with 
health benefits which traditional food could not do.  Human milk oligosaccharides (HMOs) are 
the third major component in human milk, only after lactose and lipid.45-47 Concentrations and 
components of HMOs vary depending on the stages of lactation.48-49 Particularly, one liter mature 
human milk contains about 12-14 grams HMOs.50-56 The structures of about 130 discovered HMOs 
have been elucidated.57-59 The major building blocks of HMOs are 5 monosaccharides, including 
D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-Fucose (Fuc), and N-
acetyl neuraminic acid (Neu5Ac). Even though HMOs were first discovered and confirmed in 
1950s, a comprehensive understanding of their functions is still out of reach, due to their inherit 
diversity and complexity.  Increasing evidences show that HMOs can provide significant beneficial 
effects to the health of breast-fed infants through several mechanisms. For instance, HMOs could 
serve as prebiotics to promote the growth of desired bacteria in infant’s intestine.47-48, 60-63 Besides, 
HMOs are antiadhesive antimicrobials by serving as a receptor to prevent pathogen attachment to 
infant mucosal surfaces.64-68 In addition, evidence has demonstrated that HMOs can modulate 
epithelial and immune cell responses, and reduce excessive mucosal leukocyte infiltration and 
activation, which in turn decreases the risk of necrotizing enterocolitis (NEC), one of the most 
common fatal disorders in preterm infants.69-70 Furthermore, sialylated HMOs may also provide 
necessary nutrients for the development of brain and cognition of infants.71-74 
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    Even though the general functions of HMOs has been explored and discovered, the 
functional roles of individual HMOs are far less clear because of very limited accesses towards 
sufficient amount of structurally defined HMOs. To date, only a handful of short-chain HMOs can 
be produced in large scale and the supply of more complicated and branched HMOs is highly 
demanded.  
Until now, only a few approaches has been developed for the synthesis of a small number of 
well-defined HMOs.48, 75-84 For example, Schmidt developed strategies to synthesize some highly 
branched HMOs by solution-phase and solid-phase synthesis.78, 80-81 Enzymatic methods have also 
been employed to achieve relatively simple structures.77 One of the biggest roadblocks in previous 
synthesis remains to be small quantity and limited variety of HMOs needed for biofunctional 
studies. Recently, we have developed an efficient Core Synthesis/Enzymatic Extension (CSEE) 
strategy for rapid preparation of N-glycan libraries.85 In this study, similar strategy was 
successfully applied for HMOs synthesis. Briefly, 3 core oligosaccharides with one or two GlcNAc 
residue(s) at the non-reducing end were first synthesized by convergent assembly of 3 simple 
building blocks followed by extension of the cores by 4 robust glycosyltransferases to produce a 
library of 31 HMOs in my first project (Figure.3.1). After that we utilize the same CSEE strategy 






Figure 3.1 HMOs synthesized by the Core Synthesis/Enzymatic Extension (CSEE) 





Figure 3.2 68 HMOs synthesized by the Core Synthesis/Enzymatic Extension (CSEE) 
strategy starting with new core structure 
3.2 Results and Discussion 
3.2.1 Convergent core synthesis 
Previous studies highlighted the complexity and challenges associated with synthesizing 
HMOs via block coupling strategy. Schmidt developed sequential synthesis of lactose-containing 
oligosaccharides, including HMO lacto-N-tetraoside based on Solid-Phase Synthesis concept.80 
Madsen used one-pot glycosylations to achieve several human milk oligosaccharides.79 Both of 
the methods can synthesize linear and simple oligosaccharides with obvious limitations in 
achieving more complex HMOs, especially highly branched ones.  In this study, we developed an 
efficient and versatile methodology that utilized oligosaccharyl thioethers and oligosaccharyl 
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bromides as convergent donors for glycosylation, enabling branching assembly in one or two steps 
of glycosylations with excellent stereoselectivity and yields.  
    We envisaged that protected lactose 1 (Figure 2) would be a versatile precursor for the 
synthesis of core structures, including symmetric and asymmetric ones, as C4, C6-hydroxyl groups 
(OH) on Gal are protected by benzylidene and the C3-OH is unprotected for chemical 
glycosylation. In order to achieve the selective protection of building block 1, C3-OH group was 
selectively protected by 4-Methoxybenzyl ether (PMB) using standard condition, followed by C4, 
C6-OH protection with benzylidene group. In order to furnish the target cores, two oligosaccharyl 
thioethers and oligosaccharyl bromide were prepared (Figure 2).  
 
 
Figure 3.3 The three versatile building blocks for the assembly of the three core 
structures 
3.2.2 Synthesis of building blocks 
The synthesis of precursor 1 began with lactose peracetate, which was converted to the β-
lactoside 4 by reaction with benzyl alcohol in the presence of BF3∙Et2O, followed by deacetylation 
with NaOMe/MeOH condition to furnish compound 5.  Then 5 was treated with dibutyltin oxide, 
followed by the reaction with 4-Methoxybenzyl chloride to provide selective 3’-O-PMB protected 
lactoside with fair yield, which has been extensively studied.83, 86  The following Benzylidene 
protection on 4’, 6’-OH was conducted with Benzaldehyde dimethyl acetal, catalyzed by 
Camphorsulfonic acid (CSA), to get compound 6. The perbenzylation of the remaining hydroxyls 
of 6 was performed by using sodium hydride and benzyl bromide in anhydrous DMF to give 
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compound 7. After removing PMB protecting group of 7 treated with 2, 3-Dichloro-5, 6-dicyano-
1, 4-benzoquinone (DDQ), building block 1 was achieved (Scheme 1). 
 
 
Figure 3.4 Synthesis of Building Block 1. Reagents and conditions 
 
(a) (i) BF3∙Et2O, BnOH, DCM, 4 Å MS; (ii) NaOMe, MeOH, 50% over two steps; (b) (i) 
n-Bu2SnO, MeOH, reflux; (ii) PMBCl, TBAI, Toluene, 4 Å MS reflux, 40%; (c) PhCH(OMe)2,  
DMF, CSA, 75%; (d) BnBr, NaH,  DMF, 95%; (e) DDQ, DCM/PBS Buffer=9:1, 90%. 
Lactosamine building block 3 was initially envisioned to be synthesized using a straightforward 
fashion by coupling monosaccharide 9 and 10 (Scheme 2A). Unfortunately, only minor desired 
product was isolated by silica gel chromatography, and substantial amount of byproduct 11 was 
generated through a thioether migration reaction.87 Therefore, a Koenigs–Knorr reaction coupling 
approach was carried out by installing C4 hydroxy group of glucosamine with high yield (Scheme 






Figure 3.5 Synthesis of Building Block 3. (A) Failed reaction; (B) Successful reaction 
Reagents and conditions: (a) Et3SiH, TfOH, 4Å MS, -78°C, 85%; (b) TMSOTf, DCM, 
4Å MS,-20°C; (c) AgOTf, DCM/Toluene,70%. 
 
3.2.3 Synthesis of core oligosaccharides 
 
Figure 3.6 Synthesis of HMO1 
Reagents and conditions: (a) Et3SiH, PhBCl2, 4 Å MS, DCM, -78°C, 85%; (b) 2, AgOTf, 
2,4,6-Collidine, -20 °C, 85%; (c) (i) Ethanediamine, n-BuOH; (ii) Ac2O, Pyridine, DMAP; (d) (i) 
NaOMe/MeOH 75% over two steps; (ii) H2, Pd(OH)2/C, 80% over two steps. 
 
Glycosylation of 3’-O-unprotected acceptor 1 with donor 3 proceeded at -20°C under 
AgOTf/NIS conditions to furnish the desired tetrasaccharide 16 in 85% yield. Then selective 
opening of the benzylidene ring at C6 of 16 using Et3SiH/PhBCl2 condition provided 6’-O-
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unprotected acceptor 17 in 80% yield. The fully protected pentasaccharide was initially attempted 
to be synthesized by a convergent glycosylation of acceptor 17 and thiol donor 18. Unfortunately, 
the desired product was not detected by TLC and ESI mass spectrometry analysis (Scheme 4A). 
Several other donors including oligosaccharyl trichloroacetimidate and thioethers donors were 
tried to install the pentasaccharide, but no product was detected. The big challenge should be 
caused by the bulky benzyl group on 4’-OH position, which has very large steric hindrance and 
stops the glycosylation on 6’-OH position, even though primary alcohol is very nucleophilic. 
Therefore, 4’, 6’-O-unprotected lacto-N-tetraose 19 was proposed as acceptor for the 
glycosylation. Removal of the 4’, 6’-O-benzylidene of 16 by treatment with ethanethiol in the 
presence of TsOH afforded acceptor 19. Glycosylation of acceptor 19 with glycosyl bromide 2 to 
achieve the protected target pentasaccharide 20 proceeded smoothly and regioselectively by use 
of AgOTf as Lewis acid at -20 °C in an excellent yield (85%). The two phthalimides of 20 were 
then converted into acetamides 21, followed by the global deprotection of Ac and Bn groups. The 






Figure 3.7 Synthesis of HMO2 
(A) Failed reaction; (B) Successful reaction. Reagents and conditions: (a) NIS, TfOH, 
DCM, 4 Å MS,-20°C, 85%; (b) Et3SiH, PhBCl2, DCM, -78 °C. 80%; (c) NIS, AgOTf, DCM, 4 
Å MS,-20°C; (d) TsOH, EtSH, DCM, 90%; (e) 2, AgOTf, 2,4,6-Collidine, DCM, 4 Å MS, -20°C 
85%; (f) (i) Ethanediamine, n-BuOH; (ii) Ac2O, Pyridine, DMAP 62% over two  steps; (g) (i) 
NaOMe/MeOH; (ii) H2, Pd(OH)2/C, 80% over two steps. 
 
 
AgOTf promoted Glycosylation of 3’-O-unprotected acceptor 1 with donor 2 proceeded at 
-20°C to furnish the trisaccharide 22 in a good yield of 85%. Then deprotection of the 4’, 6’-O-
benzylidene of 22 by treatment of EtSH/TsOH provided the dialcohol 23. Glycosylation of 
acceptor 23 with thiol donor 3 by treatment of AgOTf/NIS condition at -20°C to achieve the 
protected target pentasaccharide 24 in 70% yield.  The two phthalimides of 24 were then converted 
into acetamides 25.  Complete deprotection of 25 was achieved by hydrogenolytic debenzylation 
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(Pd(OH)2/C, H2) and complete de-O-acetylation using sodium methoxide in methanol, resulting in 
core oligosaccharide HMO3 in a total yield of 67% over the four steps (Figure 3.8). 
 
 
Figure 3.8 Synthesis of HMO3 
Reagents and conditions: (a) AgOTf, 2, 4, 6-Collidine, DCM, 4Å MS, 85%; (b) TsOH, 
EtSH, DCM, 80%; (c) 3, NIS, AgOTf, DCM,  4Å MS, -20°C,70%; (d) (i) Ethanediamine, n-
Butanol; (ii) Ac2O, Pyridine, DMAP; 70% over two steps; (e) (i) NaOMe, MeOH; (ii) Pd(OH)2, 
H2.  95% over two steps 
 
3.2.4 Enzymatic extension of core structures 
A total of 31 HMOs were enzymatically synthesized starting from the 3 core structures 
(HMO1, HMO2, HMO3) via an enzymatic extension approach using 4 robust GTs: 1,4 
galactosyl-transferase from Neisseria meningitidis (LgtB),88 2,6-sialyltransferase from 
Photobacterium damselae (Pd2,6ST),89 C-terminal 66 amino acids truncated 1,3-
fucosyltransferase from Helicobacter pylori (Hp1,3FT),90 and 1,2-fucosyltransferase from 
Helicobacter mustelae (Hm1,2FT).91  All GTs were from bacteria and had high expression levels 
in Escherichia coli, high activity, and relatively relaxed substrate tolerance. As shown in Figure 
3A, glycans HMO11-HMO16 were prepared starting with the chemically prepared core HMO1. 
Briefly, in a 2 mL reaction system, 30 mg of HMO1 (20 mM) was incubated with Gal (20 mM), 
MgCl2 (20 mM), ATP (20mM), UTP (20mM) and variant amount of BiGalK, BiUSP and LgtB.
92 
(Figure 3D) After overnight reaction, the mixture was terminated by boiling for 10min and 
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analyzed by MAlDI-MS which shows a single peak at m/z 1095.748, corresponding to HMO11 
[M+Na] +. Meanwhile, on the HPLC-ELSD (Evaporative Light Scattering Detector) profile, a new 
peak (TR= 11.946 min) was observed. The reaction mixture was purified by HPLC using a 
water/acetonitrile gradient elution, yielding 40mg of HMO11 (93% yield). The purified HMO11 
(99% pure) was then utilized for the syntheses of HMO12-HMO16 (Figure 3A) catalyzed by 
Pd2,6ST, and 1,2FT, 1,2FT respectively (see ESI for details). Interestingly 1,3FT can 
specifically distinguish the GlcNAc from terminal Gal GlcNAc and 1,2FT preferentially 
attach to terminal Gal. We basically use this feature to biosynthesize Lewis X (Lex) and Lewis Y 
(Ley). In addition, difucosylated LacNAc motif [Fuc 1, 2-Gal- 1, 4-(Fuc 1, 3-)GlcNAc] was 
also generated while using Hm 1,2FT.  The synthesis of asymmetric bi-antennary HMO2x and 
HMO3x (Figure 3B&C) were carried out by enzymatic extension of core HMO2 and HMO3. 
Asymmetric Core HMO2 and HMO3 can more efficiently take advantage of different substrate 
specificities of GTs over symmetric HMO1 via coupling a Gal to the terminal GlcNAc of one 
antennary. For example, to obtain HMO311, the Gal from GlcNAc branch was sequentially 
extended by Hm 1,2FT, Hp 1,3FT and LgtB . (Figure 3C) In contrast, HMO310 were 
sequentially synthesized by Hm 1,2FT, LgtB and Hp 1,3FT (Figure 3C). Such synthetic routes 





Figure 3.9 Enzymatic extension of human milk oligosaccharides 
 
(a) LgtB, BiGalK, AtUSP, Gal, ATP, UTP, Mg2+; (b) Pd2,6ST, NmCSS, Neu5Ac, CTP, 
Mg2+; (c) Pd2,6ST, NmCSS, Neu5Gc, CTP, Mg2+; (d) Hp 1,3FT, GDP-Fuc, Mn2+; (e) 
Hm 1,2FT, GDP-Fuc, Mn2+. LgtB, Neisseria meningitidis 1,4 galactosyltransferase; BiGalk, 
Bifidobacterium infantis galactokinase; AtUSP, Arabidopsis thaliana pyrophosphorylase; 
Pd2,6ST, Photobacterium damselae 2,6-sialyltrans-ferase; NmCSS, Neisseria meningitidis 
CMP-sialic acid synthetase; Hp 1,3FT, C-terminal 66 amino acids truncated Helicobacter pylori 
1,3-fucosyltransferase; Hm 1,2FT, Helicobacter mustelae 1,2-fucosyltransferase. 
After we published the first library of human milk oligosaccharides. We continue to expand 
our second library of HMOs based on eight core structures which were synthesized by either 
enzymatic or chemical approach. A total 69 HMOs were enzymatically synthesized using 10 
robust GTs: 1,4 galactosyl-transferase from Neisseria meningitidis (LgtB),88 2,3-
sialyltransferase from Pasteurella multocida (PmST1m) with reduced α2,3-sialidase activity,93 1,3-
N-acetyulglucosaminyltransferase from Helicobacter pylori (LgtA),94 2,6-sialyltransferase from 
Photobacterium damselae (Pd2,6ST),89 C-terminal 66 amino acids truncated 1,3-
fucosyltransferase from Helicobacter pylori (Hp 1,3FT),90 1,2-fucosyltransferase from 
Helicobacter mustelae (Hm 1,2FT),91  1,4-galactosyltransferase from Neisseria meningitidis 
39 
 
(LgtC),95  1,3-N-acetyulgalactosaminyltransferase from Haemophilus influenza (LgtD),96  1,3-
galactosyltransferase from bovine (α1,3GalT), 97  and  1,3/4-fucosyltransferase from Helicobacter 
pylori(1,3/4 FucT). 98 All these glycotransferases were expressed in E.Coli system and have 
relatively high substrate tolerance. The 9 new core structures, either chemically or enzymatically 
synthesized, were utilized to expand the whole human milk oligosaccharides library.  
 
 
Figure 3.10 Enzymatic extension of Core Lac and LNnTof human milk oligosaccharides 
 
As shown in Figure 3.4, glycans H0401-H0411 were prepared starting with core H0400. 
Briefly, in enzymatic reaction system, H0411 (20 mM) was incubated with sugar nucleotides (20 
mM), MnCl2 (20 mM) and variant amount of corresponding glycotransferases. After that, H0408-
H0411 were obtained by extending H0403, H0404, H0407 via CstII, PmST1 and Pd2,6ST. 
H0601-H0607 were prepared starting with core H0600 via 1,3FucT, Hm 1,2FucT, LgtA, 
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PmST1 and Pd2,6ST. H0608, H0609 were achieved by further extending H0601 and H0602 
respectively via PmST1 and 1,3FucT. 
 
 
Figure 3.11 Enzymatic extension of Core pLNnH and LNT 
 
As shown in Figure 3.5, glycans H0701-H0706 were prepared starting with core H0700 
via 1,3FucT, Hm 1,2FucT, LgtA, PmST1. H1001-H1005 were obtained by extending core 
H1000 via 1,3/4FucT, Hm 1,2FucT, PmST1, Pd26ST, H1006, H1007 were obtained by 





Figure 3.12 Enzymatic extension of Core pLNnO, GloboH, and Deviant Structure 
 
As shown in Figure 3.6, glycans H0801 were prepared starting with core H0800 via 
PmST1. Globo H series was starting from H0400. We stepwisely use LgtC, LgtD, LgtD, 
Hm 1,2FucT to get H0500, H0503, H0504, H0505. H0501, H0502 were obtain by using PmsT1 
and Pd26ST starting from H0500. H1101 and H1102 were prepared by PmsT1 and Pd26ST 
starting frm H1100. CstII further transfer a Neu5Ac to H1101 to form H1103. Hm 1,2FucT 





Figure 3.13 Enzymatic extension of Core LNH 
 
 
Figure 3.14 Enzymatic extension of Core LNH 
 
As shown in Figure 3.7, Figure 3.8, glycans H0901, H0902, H0905, H0906, H0911 were 
prepared starting with core H0900 via LgtB, Hm 1,2FucT, 1,3/4FucT, PmST1, Pd26ST. After 
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that we branch these 5 structures to get another 11 HMOs (H0912, H0908, H0909, H0907, H0914, 
H0913, H0910, H0915, H0903, H0904.  We transfer either fucose or Sialic acid to the terminal 
Gal of asymmetric bi-antennary core H0900 to protect lower chain of core H0900. Therefore, we 
utilize different glycotransferases to sequentially extend upper chain of core H0900. According to 
this strategy, we synthesized a 16 HMOs based on H0900. 
 
3.3 Conclusion 
In summary, we have utilized our well-developed CSEE strategy for efficient synthesis of a 
library of structure-defined HMOs, which was assisted with rapid HPLC purification.  The 
combination of CSEE and HPLC purification allows us to deliver diverse and high purity of 31 
homogenous HMOs. These HMOs are valuable materials for bioactivity evaluation as well as 
glycan analysis. In this work, oligosaccharyl thioethers and oligosaccharyl bromide were 
consistently utilized as chemical glycosylation donors for the convergent installation of branched 
lactose-terminated antennae. This general and efficient method furnished 3 core oligosaccharides 
with high stereoselectivity and excellent yields. This work further confirmed that any GlcNAc-
terminated glycans could be extended to 5 or more glycans, including LeX and SLeX, which are 
very important epitopes in glycobiology.  The CSEE demonstrated a practical way to harvest 
diverse and complex HMOs with defined structures for various applications. The “mass” 
production of more homogenous HMOs and bioactivity evaluation are underway.  
After completion of first version of library of HMOs. We chemoenzymatically synthesize 
another 69 HMOs via 10 robust glycotransferases based on 9 core structures with reasonable yield 
and high purity in milligram scale. The same rapid HPLC separation method was applied on second 
version of library of HMOs. The CSEE and HPLC method provided an efficient and practical way 
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to diversify the complicated HMOs in a semi-preparative scale without tedious, complicated and 
time-consuming purification process comparing to chemical synthesis. 
3.4 Experimental Sections 
General Methods: All chemicals were purchased as reagent grade and used without 
further purification. Anhydrous dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran 
(THF), N, N-dimethyl formamide (DMF), toluene, and methanol (MeOH) were purchased from a 
commercial source without further distillation. Pulverized Molecular Sieves MS-4 Å (Aldrich) for 
glycosylation was activated by heating at 350 °C for 3 h. All reactions were performed with dry 
solvents and under nitrogen unless otherwise stated. Thin-layer chromatography (TLC) with 60 
F254 silica gel plastic plates were detected visualized under UV (254 nm) and/or by staining with 
a solution of 10 ml anisaldehyde and 10 ml 95% H2SO4 in 400 mL Ethanol, followed by heating 
on a hot plate. Column chromatography was carried out on silica gel (EMD 230-400 mesh ASTM) 
and P2 gel (Bio-rad). Optical rotation values were measured using a PerkinElmer Model 343 
polarimeter at the ambient temperature in specified solvents.  1H NMR spectra were recorded on 
a Bruker AVANCE 400 (400 MHz) or Bruker AVANCE 500 (500 MHz) spectrometer at 25 °C. 
All 1H Chemical shifts (in ppm) were assigned according to CDCl3 (δ= 7.24 ppm) or D2O (δ = 
4.79 ppm). 13C NMR spectra were obtained with Bruker AVANCE 400 spectrometer and 
calibrated with CDCl3 (δ = 77.00 ppm). Coupling constants (J) are reported in hertz (Hz). Splitting 
patterns are described using the following abbreviations: s, singlet; brs, broad singlet; d, doublet; 
t, triplet; q, quartet; dd, doublet of doublet; m, multiplet. 1H NMR spectra are reported in the 
following order: chemical shift, multiplicity, coupling constant(s), and number(s) of protons.  All 
NMR signals were assigned on the basis of 1H NMR and 13C NMR experiments. High resolution 
MALDI mass spectra were recorded on a Bruker Ultraflextreme spectrometer.  
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    Neu5Ac and Neu5Gc were purchased from Carbosynth Limited. ATP and CTP were 
purchased from Sigma. Thermosensitive Alkaline Phosphatase from shrimp (FastAP) was 
purchased from Thermo Scientific. Other enzymes including Neisseria meniningitidis 1,4-
galactosyltransferase (NmLgtB), 2,6-sialyltransferase from Photobacterium damslae (Pd2,6ST) 
, C-terminal 66 amino acids truncated Helicobacter pylori  1,3-fucosyltransferase (Hp 1,3FT) 
, Helicobacter mustelae 1,2-fucosyltransferase (Hmα1,2FT), CMP-sialic acid synthetase from 
N. meningitides (NmCSS) were expressed and purified as previously described. Enzymes were 
then desalted against 50 mM Tris-HCl, 100 mM NaCl, and 50% glycerol, and stored at -20 °C for 
long term use. Sugar nucleotides uridine 5’-diphospho-galactose (UDP-Gal), cytidine 5’-
monophospho- N-acetylneuraminic acid (CMP-Neu5Ac), cytidine 5’-monophospho- N-
Glycolylneuraminic acid (CMP-Neu5Gc) and guanoside 5’-diphospho-L-fucose (GDP-Fuc)  were 
prepared as described below. 
General Procedures 
    A) Transformation of N-Phth to NHAc procedure: A mixture of N-Phth protected 
oligosaccharide was dissolved in n-BuOH at room temperature, followed by addition of 
ethylenediamine (n-BuOH: ethylenediamine = 2:1). After being stirred at 90 °C for 12 h, the 
mixture was evaporated in vacuo to give a residue for the next step without further purification. 
To a solution of the residue in pyridine was added Ac2O. After being stirred at room temperature 
for 12 h, the solution was diluted with EtOAc and washed with aqueous 1 M HCl, saturated 
aqueous NaHCO3, and brine solution. The organic layer was dried over Na2SO4, filtered, and 
evaporated in vacuo to give a residue, which was purified by silica gel column chromatography to 
give NHAc compound. 
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    B) Deacetylation procedure: Ac-protected oligosaccharide was dissolved in MeOH, and 
NaOMe in MeOH was added until pH was about 10. After stirring at room temperature for 12 h, 
the solution was neutralized with ion-exchange resin (H+), and then filtered. The residue was 
concentrated under vacuo to afford the desired deacetylated product.  
    C) Deprotection of benzyl group: Pd(OH)2 on carbon was added to a solution of 
protected oligosaccharide in MeOH/H2O (10/1). The mixture was stirred under 1 atmosphere of 
hydrogen. After being stirred for 24 h, the mixture was filtered through a PTFE syringe filter and 
concentrated in vacuo. The residue was purified by Bio-Gel P-2 (BIO-RAD) column 
chromatography using water as eluent. The product was then lyophilized to get target compound 
as white powder.  
    D) Production of oligosaccharyl bromide: Add peracetylated oligosaccharide 
portionwise to a stirred solution of HBr (33%) in glacial acetic acid (20.0 ml) at 0 °C. After all the 
sugar has been added, the reaction mixture was stirred at room temperature for 45 min.  TLC 
analysis (Hexanes: Ethyl acetate=1:1) indicates formation of product and consumption of starting 
material. Then the reaction was quenched by ice water (200 ml) and then extract the product with 
DCM (2 × 200 ml). Wash the combined organic extracts with a solution of NaHCO3 (aq., sat., 2 × 
200 ml), dry with Na2SO4, filter and then concentrate in vacuo. The crude product was used 
without further purification. 
E) General methods for enzyme treatment and HPLC purification In general, 31 HMOs were 
enzymatically synthesized by 4 glycosyltransferases (NmLgtB, Pd2,6ST, p,3FT, Hm1,2FT) 
in the nearly same reaction condition.  Another 69 HMOs were enzymatically synthesized by total 
10 glycosyltransferases (LgtA, LgtB, LgtC, LgtD, p,3FT, p,3/4FT, Hm1,2FT, PmST1, 
Pd26ST, CstII) Reactions contain 50 mM Tris-HCl (pH 8.0), 10 mM of acceptor HMOs, 12 mM 
47 
 
of sugar nucleotide (or its corresponding synthetase), 10 mM of MnCl2, and varying amounts of 
Glycotransferases. FastAP (1 U/200 L) was also added to digest the reaction byproduct UDP to 
drive reaction forward. Reactions incubated at 37 °C for overnight, and monitored by HILIC-
ELSD (Waters XBridge BEH amide column, 130 Å, 4.6 mm × 250 mm under a gradient running 
condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 
mL/min; B%: 65-50% within 25 min)). The desired products were detected by a high-efficient 
ELSD (evaporative light scattering detector) which increases the sample concentration to minimize 
the noise and deliver higher sensitivity. After over 90% acceptor converted, the reaction was 
quenched by boiling for 10 min, followed concentration by rotary evaporator. HPLC-A210nm was 
then used to purify target HMOs using a semi-preparative column (Waters XBridge BEH amide 
column, 130 Å, 5 m, 10 mm × 250 mm) under a gradient running condition which are solvent 
A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65-
50% within 25 min.85 MS data for purified HMOs were obtained by ESI-MS and MALDI-MS. 
 
    Benzyl O-(4, 6-O-benzylidene-3-O-(4-methoxybenzyl)- β-D-galactopyranosyl)-
(1→4)- β-D-glucopyranoside (6) 
    A suspension of benzyllactose 5 (12.0 g, 27.78 mmol) and Bu2SnO (7.6 g, 30.54 mmol) 
in anhydrous MeOH (100 mL) was heated to reflux and stirred for 8 h. The solvent was removed 
in vacuo. Then the residue was dissolved in dry toluene (100 mL). p-Methoxybenzyl chloride (3.76 
mL, 20.37 mmol), tetrabutylammonium iodide (2.05 g, 11.10 mmol), and 4 Å molecular sieves (5 
g) were added. The resulting mixture was heated to reflux for another 8 h and then cooled to room 
temperature. The suspension was filtered through a Celite pad and the filtrate was concentrated 
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and chromatographied (dichloromethane-methanol=6:1) to afford 9.2 g of crude product (60% 
yield).  
    Benzaldehyde dimethyl acetal (2.75 mL, 18.33 mmol) was added to a solution of the 
above crude product (7.8 g, 14.10 mmol) in anhydrous Dimethylformamide (100 ml), then 
Camphorsulfonic acid was added to adjust the PH to about 2.0-3.0. The reaction mixture was 
stirred overnight and then quenched with triethylamine. The mixture was concentrated in vacuum. 
The residue was purified by flash column chromatography (dichloromethane-methanol=10:1) to 
give 6 as a white solid (8.47 g, 87.0%). [α]D
20 = +6.7 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): 
δ 7.48-7.51 (dd, 2H), 7.28-7.38 (m, 10 H), 6.85-6.87 (m, 2 H), 5.34  (s, 1 H), 4.87 (d, J = 11.95 
Hz, 1 H), 4.59-4.63 (m, 4 H), 4.45 (d, J = 7.8 Hz, 1 H), 4.36 (d, J = 8.1 Hz, 1 H), 4.21 (d, J = 14.0 
Hz, 1 H), 4.10 (s, 1 H), 3.92-4.00 (m, 3 H), 3.79-3.89 (m, 2 H), 3.78 (s, 3 H), 3.60-3.69 (m, 3 H), 
3.40-3.50 (m, 2 H), 3.27-3.40 (m, 4 H); 13C NMR (CDCl3, 100 MHz): δ 137.6,137.2, 130.0,129.5, 
128.5, 128.3, 128.2, 127.9, 126.3, 113.9, 103.6, 101.8, 101.1, 78.8, 74.9,74.7, 73.5, 72.7, 71.3, 
71.2, 69.1, 69.0, 66.9, 61.9, 55.3. HRMS: [M + Na]+ C34H40NaO12 calcd for 663.2417, found 
663.2420. 
    Benzyl O-(2-O-Benzyl-4, 6-O-benzylidene-3-O-(4-methoxybenzyl)- β-D-
galactopyranos-yl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (7) 
    60% NaH (2.25 g, 56.25 mmol) and BnBr (6.66 ml, 56.25 mmol) were added to a stirred 
solution of 6 (6.0g, 9.38 mmol) in DMF (60 mL) cooled at 0°C. The color of the solution changed 
to light yellow. The reaction mixture was maintained at room temperature for 4 h. Then the solution 
was quenched with MeOH. The mixture was diluted with EtOAc and washed with water. The 
organic layer was dried with Na2SO4 and concentrated. The residue was purified on a silica gel 




+7.4 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.57-7.59 (m, 2 H), 7.51-7.54 (m, 2 H), 7.42-
7.45 (m, 2 H), 7.31-7.38 (m,23 H), 7.23-7.24 (m, 2 H), 6.90-6.92 (m, 2 H), 5.51 (s, 1H), 5.25 (d, J 
= 11.0 Hz, 1 H), 4.98-5.03 (m, 2 H), 4.90 (d, J = 11.1 Hz, 1 H), 4.79-4.85 (m, 3 H),4.71-4.74 (m, 
3 H), 4.63 (d, J = 12.0 Hz, 1 H), 4.52-4.55 (m, 2 H), 4.43 (d, J = 12.0 Hz, 1 H), 4.26 (dd, J = 1.4 
Hz, 12.4 Hz, 1 H), 4.04-4.08 (m, 2 H), 3.96 (dd, J = 4.2, 11.3 Hz, 1 H), 3.90 (dd, J = 1.8, 12.5 Hz, 
1 H), 3.85 (s, 3 H), 3.79-3.83 (m, 2 H), 3.69 (t, J = 8.8 Hz, 1 H), 3.56-3.60 (m, 1 H), 3.40-3.46 (m, 
2 H); 13C NMR (CDCl3, 100 MHz): δ 159.3, 139.0, 139.0, 138.7, 138.6, 138.2, 137.6, 130.5, 129.4, 
128.9, 128.7, 128.4, 128.3, 128.1, 128.0, 127.8, 127.8, 127.6, 127.6, 127.5, 127.4, 127.3, 126.6, 
113.8, 103.0, 102.6, 101.4, 83.1, 81.9, 79.4, 78.9, 77.7, 75.9, 75.3, 75.2, 75.1, 73.8, 73.0, 71.37, 
71.1, 69.0, 68.3, 66.4, 55.3. HRMS: [M + Na]+ C62H64NaO12 calcd for 1023.4295, found 
1023.4285. 
    Benzyl O-(2-O-Benzyl-4, 6-O-benzylidene- β-D-galactopyranosyl)-(1→4)-2, 3, 6-
tri-O-benzyl- β-D-glucopyranoside (1) 
    2, 3-Dichloro-5, 6-dicyano-1, 4-benzoquinone (2.75 g, 12.10 mmol) was added to a 
solution of 7 (6.0 g, 6.05 mmol) in 9:1 CH2Cl2– Phosphate-buffered saline (200 mL) was added. 
The solution was stirred for 1.5h at room temperature and diluted with CH2Cl2. The solution was 
washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was was 
purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the product 1 (5.02 g, 95%) as 
white powder.  [α]D
20 = +15.4 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.52-7.55 (m, 4 H), 
7.20-7.45 (m, 26 H), 5.56 (s, 1 H), 5.21 (d, J = 8.0 Hz 1 H), 4.97-5.02 (m, 2 H), 4.78-4.83 (m, 4 
H), 4.65-4.73 (m, 2 H), 4.51-4.54 (m, 2 H), 4.46 (d, J = 12.3 Hz, 1 H), 4.30 (d, J = 12.3 Hz, 1 H), 
4.06-4.13 (m, 2 H), 3.93-3.97 (m, 2 H), 3.79 (dd, J = 1.3, 11.0 Hz, 1 H), 3.68 (m, 1 H), 3.55-3.60 
(m, 3 H), 3.38-3.41 (m, 1 H), 3.14 (s, 1 H) ;  13C NMR (CDCl3, 100 MHz): δ 138.9, 138.7, 138.6, 
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138.5, 137.9, 137.5, 129.2, 128.8, 128.4, 128.2, 128.0, 127.8, 127.6, 127.4, 126.5, 102.8, 102.6, 
101.5, 83.1, 81.9, 80.2, 77.6, 75.9, 75.7, 75.2, 75.1, 73.1, 72.9, 71.0, 68.9, 68.2, 66.5. HRMS: [M 
+ Na]+ C54H56NaO11 calcd for 903.3720, found 903.3725. 
    Ethyl 3, 6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (9) 
    A mixture of compound 8 (2 g, 4.09 mmol) and 4 Å molecular sieves (2 g) in dry CH2Cl2 
was stirred at room temperature under nitrogen for 2 h. Triethylsilane (2.1 mL, 13.1 mmol) and 
TfOH (1.05 mL, 11.9 mmol) were sequentially added at - 78 °C. The reaction mixture was stirred 
at -78 °C for 2 h and then quenched with MeOH (2 mL) and Et3N (2 mL). The resulting mixture 
was filtered. The filtrate was diluted with CH2Cl2 and washed with aqueous NaHCO3, brine, dried 
over Na2SO4, and concentrated. The residue was purified on a silica gel column (Hexanes: EtOAc 
= 5:1) to afford the product 9 (1.85 g, 92.5%) as white powder. [α]D
20 = +91.0 (c 1.0, CHCl3). 
1H 
NMR (CDCl3, 400 MHz): δ 7.82 (d, J = 5.9 Hz, 1 H), 7.66-7.72 (m, 3 H), 7.28-7.42 (m, 5 H), 7.03-
7.10 (m, 2 H), 6.92-7.00 (m, 3 H), 5.32 (d, J = 9.9 Hz, 1 H), 4.80 (d, J = 12.0 Hz, 1 H), 4.54-4.70 
(m, 3 H), 4.25-4.34 (m, 2 H), 3.80-3.89 (m, 3 H), 3.70-3.73 (m, 1 H), 2.59-2.72 (m, 2 H), 1.19 (t, 
J = 7.3 Hz, 3 H); 13C NMR (CDCl3, 100 MHz): δ 168.1, 167.6, 138.2, 137.7, 134.0, 133.9, 131.6, 
128.5, 127.9, 127.9, 127.8, 127.5, 123.5, 123.3, 81.2, 79.7, 78.0, 74.5, 74.2, 73.78, 70.7, 54.5, 24.0, 
15.0. HRMS: [M + Na]+ C30H31NNaO6S calcd for 556.1770, found 556.1760. 
    Ethyl 2, 3, 4, 6-tetra-O-acetyl- β-D-glucopyranosyl-(1→4)-3, 6-di-O-benzyl-2-
deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (3) 
    2, 3, 4, 6-Tetra-O-acetyl-β-D-galactosyl bromide (3.35 g, 8.17 mmol) was prepared by 
following general procedure (D).  Then the bromide donor (3.35 g, 8.17 mmol) and 3, 6-di-O-
benzyl-2-deoxy- 2-phthalimido-1-thio-β-D-glucopyranoside 9 (2.64 g. 5.43 mmol) were dissolved 
in a mixture of dry toluene and CH2Cl2 (1:1, 30 mL). Powdered molecular sieves (4 Å) were added 
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and the mixture was stirred under nitrogen for 1 h. The flask was wrapped in aluminum foil and 
cooled to −45°C. AgOTf (2.79 g, 10.86 mmol) dissolved in dry toluene (20 mL) was added during 
1 h under the exclusion of light. After additional stirring for 30 min at −45°C, the reaction mixture 
was quenched by aqueous Na2S2O3. The mixture transferred to a separatory funnel via a Celite-
packed glass filter funnel. The organic phase was separated, dried with Na2SO4, filtered, and 
concentrated. Purification of the residue by silica gel column chromatography 
(Hexanes:EtOAc=4:1) gave compound 3 (5.81 g, 80%). [α]D
20 = +31.0 (c 1.0, CHCl3). 
1H NMR 
(CDCl3, 400 MHz): δ 7.77 (d, J = 6.3 Hz, 1 H), 7.62-7.66 (m, 3 H), 7.29-743(m, 5 H), 7.01(d, J = 
7.0 H), 6.82-6.92 (m, 3 H), 5.13-5.28 (m, 3 H), 4.78-4.87 (m, 3 H), 4.62 (d, J = 7.9 Hz, 1 H), 4.43-
4.51 (m, 2 H), 4.20-4.28 (m, 2 H), 4.09 (t, J = 9.5 Hz, 1 H), 3.89-4.02 (m, 2 H), 3.79 (s, 2 H), 3.64 
(t, J = 6.8 Hz, 1 H), 3.56 (d, J = 10.0 Hz, 1 H), 2.55-2.75 (m, 2 H), 2.06 (s, 3 H), 2.02 (s, 6 H), 
1.97 (s, 3 H);  13C NMR (CDCl3, 100 MHz): δ 170.3, 170.2, 170.0, 169.2, 167.9, 167.4, 138.5, 
137.9, 133.9, 133.7, 131.6, 128.6, 128.0, 127.9, 127.9, 127.1, 123.4, 123.3, 100.3, 81.1, 79.1, 77.8, 
77.6, 74.5, 73.6, 70.4, 69.5, 67.7, 66.9, 60.7, 54.7, 23.9, 20.8, 20.7, 20.6, 20.6, 14.9. HRMS: [M + 
Na]+ C44H49NNaO15S calcd for 886.2721, found 886.2729. 
    Benzyl O-(2, 4-di-O-Benzyl-β-D-galactopyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-
D-glucopyranoside (13) 
    A mixture of compound 1 (2 g, 2.27 mmol) and 4 Å molecular sieves (2 g) in dry CH2Cl2 
was stirred at room temperature under nitrogen for 2 h. Triethylsilane (0.69 mL, 4.34 mmol) and 
PhBCl2 (0.56 mL, 4.34 mmol) were sequentially added at - 78 °C. The reaction mixture was stirred 
at -78 °C for 2 h and then quenched by the addition of MeOH (2 mL) and Et3N (2 mL). The 
resulting mixture was filtered. The filtrate was diluted with CH2Cl2 and washed with aqueous 
NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was purified on a silica gel 
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column (Hexanes: EtOAc = 5:1) to afford the product 13 (1.70 g, 85%) as white powder. [α]D
20 = 
+8.9 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.35-7.52 (m, 27 H), 7.26-7.34 (m, 3 H), 
5.03-5.16 (m, 3 H), 4.78-4.97 (m, 6 H), 4.70-4.75 (m, 2 H), 4.59-4.65 (m, 2 H), 4.52 (d, J = 7.0 
Hz, 1 H), 4.08 (t, J = 8.7 Hz, 1 H), 3.92 (d, J = 2.6 Hz, 2 H); 13C NMR (CDCl3, 100 MHz): δ 138.9, 
138.7 (2 C), 138.5, 137.6, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 127.9, 127.8, 127.7, 127.6, 
102.8, 102.6, 82.8, 81.9, 80.5, 77.0, 75.8, 75.5, 75.3, 75.2 (2 C), 75.1, 74.4, 73.4, 71.1, 68.4, 61.7. 
HRMS: [M + Na]+ C54H58NaO11 calcd for 905.3877, found 905.3867. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-
[ 3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl]-(1→6)-(2, 4-di-O-benzyl-
β-D-galac-topyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (14) 
    3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (3.0 g) was added to a 
solution of above bromide donor (4.80 g, 5.44 mmol) and 13 (800 mg, 0.907 mmol) in anhydrous 
dichloromethane (20 mL). The suspension was stirred under nitrogen for 1.5 h at room temperature 
and then cooled to -30°C. Then 2, 4, 6-collidine (0.72 mL, 5.44 mmol), and freshly dried AgOTf 
(1.40 g, 5.44 mmol) was sequentially added to the reaction mixture. After stirring for 2 h at -30°C, 
the mixture was allowed to warm up to rt overnight, diluted with CH2Cl2, filtered through Celite. 
The filtrate was diluted with CH2Cl2 and washed with aqueous NaHCO3, brine, dried over Na2SO4, 
and concentrated. The residue was purified on a silica gel column (Hexanes: EtOAc = 5:1) to 
afford the product 14 (1.33 g, 85%) as white powder. [α]D
20 = +6.4 (c 1.0, CH2Cl2). 
1H NMR 
(CDCl3, 400 MHz): δ 7.85 (t, J = 4.01 Hz, 1 H), 7.72-7.74 (m, 2 H), 7.43-7.56 (m, 2 H), 7.18-7.40 
(m, 27 H), 7.08-7.16 (m, 3 H), 6.97 (m, 2 H), 5.76-5.87 (m, 2 H), 5.62 (d, J = 8.24 Hz, 1 H), 5.39(d, 
J = 8.43, 1H),  5.16-5.24 (m, 2 H), 4.85-4.93 (m, 4 H), 4.75 (d, J = 10.6 Hz, 1 H), 4.55-4.66 (m, 3 
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H), 4.35-4.44 (m, 5 H), 4.19-4.33 (m, 5 H), 4.12 (d, J = 12.7 Hz, 1 H), 3.91 (t, J = 10.1 Hz, 1 H), 
3.71-3.86 (m, 5 H), 3.47-3.59 (m, 5 H), 3.33-3.47 (m, 2 H), 3.21 (t, J = 5.9 Hz, 1 H), 3.05(dd,  J = 
3.2, 9.7 Hz, 1 H), 2.09 (s, 3 H), 2.09 (s, 3 H), 2.02 (s, 3 H), 1.98 (s, 3 H), 1.87(d, 6 H); 13C NMR 
(CDCl3, 100 MHz): δ 170.7, 170.6, 170.1, 170.0, 169.5, 169.5, 139.1, 139.0, 138.6, 138.5, 138.4, 
137.7, 134.4, 134.0, 128.4, 128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.6, 127.5, 127.4, 127.4, 
127.1, 127.0, 126.9, 126.5, 102.4, 102.3, 99.0, 97.5, 83.1, 81.7, 81.7, 78.6, 76.2, 76.1, 75.6, 75.2, 
75.0, 74.9, 74.1, 73.1, 72.8 (2 C), 71.7, 71.6, 70.8, 70.8 (2 C), 70.5, 68.9, 68.8, 68.0, 66.8, 61.7, 
61.6, 55.1, 54.7, 20.8, 20.7, 20.7, 20.6, 20.5, 20.4. HRMS: [M + Na]+ C94H96N2NaO29 calcd for 
1739.5996, found 1739.5980. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl)-(1→3)-[ 3, 
4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl]-(1→6)-(2,4-di-O-benzyl-β-D-
galactopyr-anosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (15) 
    Following the general procedure (A) compound 14 (1.16 g, 0.66 mmol) yielded the 
compound 15 (762mg, 75% over two steps). [α]D
20 = -1.9 (c 0.4, CH2Cl2). 
1H NMR (CDCl3, 400 
MHz): δ 7.25-7.48 (m, 27 H), 7.10-7.18 (m, 3 H), 5.78 (d, J = 9.5 Hz, 1 H), 5.01-5.16 (m, 6 H), 
4.90-5.00 (m, 3 H), 4.75-4.91 (m, 4 H), 4.60-4.71 (m, 3 H), 4.41-4.55 (m, 4 H), 4.29 (d, J = 3.5 
Hz, 1 H), 3.96-4.15 (m, 5 H), 3.64-3.86 (m, 8 H), 3.52-3.64 (m, 4 H), 3.45-3.51 (m, 1 H), 3.23 (d, 
J = 9.7 Hz, 1 H), 2.07 (s, 3 H), 2.06 (s, 3 H), 2.05 (s, 3 H), 2.00 (s, 3 H), 1.99 (s, 3 H), 1.98 (s, 3 
H), 1.51 (s, 3 H); 13C NMR (CDCl3, 100 MHz): δ 170.9, 170.8, 170.6, 170.5, 170.3, 169.8, 169.3, 
169.2, 139.4, 138.9, 138.8, 138.6, 137.9, 137.4, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 
128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 126.2, 102.6, 102.5, 102.4, 101.4, 84.3, 82.4, 82.1, 79.5, 
76.7, 76.4, 76.2, 75.2, 74.9, 74.7, 74.5, 74.4, 73.3, 73.2, 72.7, 72.0, 70.9, 70.6, 68.8, 68.5, 67.9, 
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67.5, 62.0, 61.6, 54.4, 53.7, 23.6, 22.8, 20.8, 20.8, 20.7, 20.6 (3 C). HRMS: [M + Na]+ 
C82H96N2NaO27 calcd for 1563.6098, found 1563.6126. 
    2-deoxy-acetamido-β-D-glucopyranosyl-(1→3)-[ 2-deoxy-acetamido-β-D-
glucopyranos-yl]-(1→6)- β-D-galactopyranosyl-(1→4)-α,β-D-glucopyranose (HMO1) 
    Following the general procedure (B) and (C), compound 15 (400 mg, 0.26 mmol) 
yielded the compound HMO1 (152 mg, 80% over two steps). 1H NMR (D2O, 400 MHz): δ 5.15 
(d, J = 3.6 Hz, 0.55 H, Glc-1 H-1 of α form), 4.53-4.62 (m, overlap with D2O, 2.45 H, GlcNAc-1 
H-1, GlcNAc-2 H-1 and Glc-1 H-1 of β form), 4.36 (d, J = 7.7 Hz, 1 H, Gal-1 H-1), 4.07(d, J = 
2.4 Hz, 1 H), 3.58-3.95 (m, 13 H), 3.45-3.58 (m, 5 H), 3.32-3.45 (m, 4 H), 3.16-3.26 (m, 1 H), 
1.99 (s, 3 H), 1.96 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 174.9, 174.6, 102.9, 102.8 (GlcNAc-1, 
GlcNAc-2, C-1),101.1 (Gal-1, C-1), 95.7 (Glc-1, C-1 of β form), 91.8 (Glc-1, C-1 of α form), 81.7, 
78.8, 75.8 (2 C), 75.6, 73.8, 74.7, 74.3, 73.8, 73.5, 73.4, 69.86, 69.8, 69.6, 68.7, 68.4, 60.7, 60.5, 
55.6, 55.5, 22.4, 22.2.  HRMS: [M + Na]+ C28H48N2NaO21 calcd for 771.2647, found 771.2520. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-benzyl-
2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-(2-O-benzyl-4, 6-O-benzylidene-β-D-
galac-topyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (16) 
    Powdered molecular sieves (4 Å) (3.0 g) was added to a solution of Compound 3 (871 
mg, 0.96 mmol)  and 1 (652 mg, 0.74 mmol)  in anhydrous dichloromethane (20 mL). The 
suspension was stirred under nitrogen for 1.5 h at room temperature and then cooled to -30°C. 
Then NIS (260mg, 1.15mmol), and TMSOTf (35 µl, 0.19 mmol) was sequentially added to the 
reaction mixture. After stirring for 2 h at -30°C, the mixture was allowed to warm up to rt. 
overnight, diluted with CH2Cl2, filtered through Celite. The filtrate was diluted with CH2Cl2 and 
washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was 
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purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the product 16 (1.04 g, 86%) as 
white powder. [α]D
20 = +12.9 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.53-7.55 (m, 2 H), 
7.45-7.50 (m, 2 H), 7.27-7.45 (m, 27 H), 7.19 (t, J = 3.6 Hz, 2 H), 7.09-7.16 (m, 3 H), 7.02-7.06 
(m, 2 H), 6.84-6.94 (m, 5 H), 5.49 (s, 1 H), 5.47 (d, J = 7.4 Hz, 1 H), 5.35 (d, J = 3.2 Hz, 1 H), 
5.25 (dd, J = 7.9, 10.4 Hz, 1 H), 5.09 (d, J = 10.7 Hz, 1 H), 4.88-4.99 (m, 3 H), 4.85 (d, J = 12.0 
Hz, 1 H), 4.65-4.78 (m, 4 H), 4.61 (d, J = 12.0 Hz, 1 H), 4.44-4.55 (m, 3 H), 4.30-4.39 (m, 4 H), 
4.18-4.28 (m, 5 H), 4.09 (t, J = 9.3 Hz, 1 H), 3.98-4.04 (m, 2 H), 3.89-3.96 (m, 1 H), 3.80-3.89 (m 
2 H), 3.66-3.79 (m, 3 H), 3.53-3.64 (m, 2 H), 3.44-3.51 (m, 3 H), 3.38 (d, J = 10.1 Hz, 1 H), 2.93-
3.02 (m, 2 H), 2.12 (s, 3 H), 2.10 (s, 3 H), 2.05 (s, 3 H), 2.03 (s, 3 H); 13C NMR (CDCl3, 100 
MHz): δ 170.3, 170.2, 170.1, 169.2, 139.0, 138.6 (2 C), 138.5, 138.3, 137.8, 137.6, 133.5, 131.3, 
128.7, 128.6 (2 C), 128.4, 128.3 (2 C), 128.2, 128.1 (2 C), 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 
127.2, 127.1, 126.7, 126.5, 126.3, 123.1, 102.4 (2 C), 100.7, 100.6, 99.6, 83.1, 81.8, 80.9, 78.4, 
77.7, 76.0, 75.7, 75.0, 74.8, 74.7, 74.5, 74.3, 73.8 (2 C), 73.0 (2 C), 71.1, 70.9 (2 C), 70.6, 69.7, 
68.8, 68.7, 67.9, 67.0, 66.4, 60.8, 55.8, 20.9, 20.7 (2 C), 20.6. HRMS: [M + Na]+ C96H99NNaO26 
calcd for 1704.6353, found 1704.6383. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-benzyl-
2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-(2-O-benzyl-β-D-galactopyranosyl)-
(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (19) 
    To a solution of compound 16 (800 mg, 0.49 mmol) in anhydrous MeOH (10 mL) was 
added TsOH (8.4 mg) and EtSH (0.21 ml, 2.93 mmol). The reaction mixture was stirred at rt. for 
6 h and then quenched with triethylamine and evaporated under reduced pressure. The mixture 
was purified with silica column (Hexanes: Acetone = 5:1) to get white power compound 19 (702 
mg, 90%). [α]D
20 = +18.4 (c 0.5, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.38-7.52 (m, 11 H), 
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7.25-7.36 (m, 16 H), 7.22-7.26 (m, 2 H), 7.03-7.14 (m, 3 H), 6.99-7.03 (m, 2 H), 6.85-6.92 (m, 2 
H), 6.78 (d, J = 7.1 Hz, 2 H), 5.29-5.31 (m, 2 H), 5.19-5.25 (m, 1 H), 4.86-4.98 (m, 4 H), 4.83 (d, 
J = 12.2 Hz, 1 H), 4.68-4.77 (m, 3 H), 4.65 (d, J = 8.3 Hz, 1 H), 4.57-4.62 (m, 2 H), 4.46 (t, J = 
12.4 Hz, 2 H), 4.34-4.40 (m, 1 H), 4.26-4.34 (m, 3 H), 4.17-4.26 (m, 3 H), 3.95-4.08 (m, 3 H), 
3.81-3.88 (m, 1 H), 3.72-3.79 (m, 3 H), 3.64-3.72 (m, 2 H), 3.47-3.55 (m, 2 H), 3.34-3.46 (m, 5 
H), 3.17-3.23 (m, 1 H),  3.00-3.06 (m, 1 H), 2.87 (s, 1 H), 2.11 (s, 3 H), 2.08 (s, 3 H), 2.05 (s, 3 
H), 2.02 (s, 3 H); 13C NMR (CDCl3, 100 MHz): δ 170.3, 170.2, 170.1, 169.2, 138.9, 138.4, 138.3 
(2 C), 137.6, 137.5, 133.6, 131.1, 128.8, 128.4, 128.3 (3 C), 128.2 (2 C), 128.1, 127.9, 127.8, 
127.7, 127.6, 127.5, 127.4, 127.2, 126.7, 126.4, 123.2, 102.4, 102.1, 100.6, 99.0, 83.8, 82.8, 81.5, 
78.3, 77.9, 76.6, 76.4, 75.6, 74.9, 74.6, 74.3, 73.8, 73.7, 73.1, 71.0, 70.9, 70.7, 69.6, 68.3, 67.9, 
67.7, 66.9, 62.2, 60.8, 55.6, 20.8, 20.68, 20.6, 20.6. HRMS: [M + Na]+ C89H95NNaO26 calcd for 
1616.6040, found 1616.6065. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-benzyl-
2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3) )-[ 3, 4, 6-tri-O-acetyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl]-(1→6)-(2-O-benzyl-β-D-galactopyranosyl)-(1→4)-2, 3, 6-
tri-O-benzyl- β-D-glucopyranoside (20) 
    3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (3.0 g) was added to a 
solution of 19 (460 mg, 0.29 mmol), 2, 4, 6-collidine (76 µL, 0.58 mmol), and freshly dried AgOTf 
(150 mg, 0.58 mmol) in anhydrous dichloromethane (20 mL). The suspension was stirred under 
nitrogen for 1.5 h at room temperature and then cooled to -30°C. Then a solution of above bromide 
donor (460 mg, 0.29 mmol) in dichloromethane (5.0 mL) was added dropwise during 30 min to 
the reaction mixture. After stirring for 2 h at -30°C, the mixture was allowed to warm up to rt. 
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overnight, diluted with CH2Cl2, filtered through Celite. The filtrate was diluted with CH2Cl2 and 
washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was 
purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the product 20 (495 mg, 85%) as 
white powder. [α]D
20 = +11.7 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.76-7.91 (m, 4 H), 
7.49-7.56 (m, 2 H), 7.41-7.49 (m, 8 H), 7.14-7.20 (m, 2 H), 7.05-7.11 (m, 1 H), 6.97-7.04 (m, 4 
H), 6.85-6.94 (m, 3 H), 6.75 (d, J = 7.4 Hz, 2 H), 5.73 (dd, J = 9.1, 10.61 Hz, 1 H), 5.43 (d, J = 
8.3 Hz, 1 H), 5.33 (d, J = 3.5 Hz, 1 H), 5.12-5.25 (m, 2 H), 4.99 (d, J = 8.9 Hz, 1 H), 4.77-4.95 (m, 
3 H), 4.72-4.84 (m, 3 H), 4.61-4.71 (m, 2 H),  4.48-4.58 (m, 2 H), 4.33-4.47 (m, 3 H), 4.09-4.31 
(m, 8 H), 3.80-4.06 (m, 6 H), 3.65-3.80 (m, 5 H), 3.62 (d, J = 10.0 Hz, 1 H), 3.50-3.56 (m, 2 H), 
3.36-3.45 (m, 3 H),  3.20-3.27 (m, 2 H), 3.09-3.17 (m, 2 H), 2.87 (s, 1 H), 2.14 (s, 3 H), 2.11 (s, 3 
H), 2.09 (s, 3 H), 2.04 (s, 3 H), 2.02 (s, 3 H), 1.99 (s, 3 H), 1.87(s, 3 H); 13C NMR (CDCl3, 100 
MHz): δ 170.7, 170.3, 170.2, 170.0 (2 C), 169.5, 169.5, 139.1, 138.7, 138.4, 138.3 (2 C), 137.7, 
137.6, 131.2, 128.8, 128.4, 128.3 (3 C), 128.2, 128.1, 127.9 (2 C), 127.8, 127.7, 127.6 (2 C), 127.4, 
127.2, 126.5, 123.2, 102.4, 101.9, 100.7, 98.5, 97.6, 83.8, 83.1, 81.9, 78.4, 77.8, 76.5, 76.3, 75.7, 
75.1, 74.9, 74.5, 74.4, 74.4, 73.9, 72.9 (2 C), 72.0, 71.7, 71.1, 71.0, 70.8, 70.6, 69.5, 68.8, 68.1, 
67.6, 66.9, 66.6, 61.7, 60.8, 55.4, 54.7, 20.9, 20.8, 20.67, 20.6 (3 C), 20.5. HRMS: [M + Na]+ 
C109H114N2NaO35 calcd for 2033.7100, found 2033.7089. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-benzyl-
2-deoxy-acetamido-β-D-glucopyranosyl-(1→3)-[3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-
glucopy-ranosyl]-(1→6)-(4-O-acetyl-2-O-benzyl-β-D-galactopyranosyl)-(1→4)-2, 3, 6-tri-O-
benzyl- β-D-glucopyranoside (21) 
    Following the general procedure (A), compound 20 (400 mg, 0.20 mmol) yielded the 
compound 21 (232 mg, 62% over two steps). [α]D
20 = -1.0 (c 1.2, CH2Cl2). 
1H NMR (CDCl3, 400 
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MHz): δ 7.51 (m, 2H), 7.21-7.43 (m, 33 H), 5.89 (d, J = 9.5 Hz , 1 H), 5.43 (d, J = 8.4 Hz, 1 H), 
5.33 (d, J = 2.8 Hz, 1 H), 4.33-5.24 (m, 23 H), 4.24 (d, J = 8.2 Hz, 1 H), 3.94-4.10 (m, 6 H), 3.45-
3.86 (m, 15 H), 3.23 (d, J = 9.7 Hz, 1 H), 2.12 (s, 3 H), 2.11 (s, 3 H), 2.05 (s, 3 H), 2.04 (s, 3 H), 
2.01 (s, 3 H), 2.00 (s, 3 H), 1.99 (s, 3 H), 1.97 (s, 3 H), 1.94 (s, 3 H), 1.54 (s, 3 H); 13C NMR 
(CDCl3, 100 MHz):δ 170.8, 170.7, 170.4, 170.3, 170.2, 170.0, 170.0 (2 C), 169.7, 169.2, 139.4, 
138.7, 138.6 (2 C), 138.0, 137.7, 137.4, 128.7, 128.6, 128.4, 128.4 (2 C), 128.3, 128.2, 128.1, 
128.0, 127.9 (2 C), 127.8, 127.7, 127.6, 127.0, 102.6, 102.3, 101.1, 100.7, 100.0, 83.8, 82.4, 79.5, 
78.3, 77.9, 76.2 (2 C), 75.6, 75.0, 74.9, 74.6, 74.4, 73.9, 73.5, 73.3, 73.2 (2 C), 73.2, 70.9, 70.8, 
70.7, 70.6, 70.0, 69.4, 68.3, 68.0, 67.9, 67.9, 67.3, 66.9, 61.5, 60.8, 54.5, 53.6, 20.9, 20.8, 20.7 (3 
C), 20.6 (3 C), 20.5 (2 C).  HRMS: [M + Na]+ C99H116N2NaO34 calcd for 1899.7307, found 
1899.7287. 
    β-D-galactopyranosyl-(1→4)-2-deoxy-acetamido-β-D-glucopyranosyl-(1→3)-[ 2-
deoxy-acetamido-β-D-glucopyranosyl]-(1→6)- β-D-galactopyranosyl-(1→4)-α,β-D-
glucopyranose (HMO2) 
    Following the general procedure (B) and (C), compound 21 (200 mg, 0.11 mmol) 
yielded the compound HMO2 (87 mg, 90%). 1H NMR (D2O, 400 MHz): δ 5.11 (d, J = 3.6 Hz, 
0.42 H, Glc-1 H-1 of α form), 4.53-4.62 (m, 1.58 H, GlcNAc-1 H-1, Glc-1 H-1 of β form), 4.50 
(d, J = 8.4 Hz, 1 H, GlcNHAC-2 H-1), 4.36 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.31 (d, J = 8.0 Hz, 1 
H, Gal-2 H-1), 4.03 (d, J = 3.0 Hz, 1 H), 3.77-3.92 (m, 5 H), 3.40-3.77 (m, 21 H), 3.30-3.38 (m, 2 
H), 3.17 (t, J = 8.9 Hz, 1 H), 1.95 (s, 3 H), 1.92 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 174.9, 
174.5, 103.0, 102.8, 102.7 (GlcNAc-1, GlcNAc-2, Gal-2, C-1), 101.0 (Gal-1, C-1), 95.7 (Glc-1, 
C-1 of β form), 91.8 (Glc-1, C-1 of α form), 81.8, 78.9, 78.8, 78.1, 75.8, 75.3,  74.7, 74.5, 74.3, 
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73.8, 73.4, 72.5, 72.1, 71.4, 71.2, 70.9, 69.6, 68.5, 68.4, 61.0, 60.1, 60.0, 59.8, 55.5, 55.2, 22.4, 
22.2. HRMS: [M + Na]+ C34H58N2NaO26 calcd for 933.3175, found 933.3195. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-
(2-O-benzyl-4, 6-O-benzylidene-β-D-galactopyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-
glucopy-ranoside (22) 
    3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (2.0 g) was added to a 
solution of above bromide donor 2 (1.2 g, 2.43 mmol) and 1 (500 mg, 0.61 mmol) in anhydrous 
dichloromethane (20 mL). The suspension was stirred under nitrogen for 1.5 h at room temperature 
and then cooled to -30°C. Then 2, 4, 6-collidine (0.32 mL, 2.43 mmol), and freshly dried AgOTf 
(624 mg, 2.43 mmol) was sequentially added to the reaction mixture. After stirring for 2 h at -
30°C, the mixture was allowed to warm up to rt overnight, diluted with CH2Cl2, filtered through 
Celite. The filtrate was diluted with CH2Cl2 and washed with aqueous NaHCO3, brine, dried over 
Na2SO4, and concentrated. The residue was purified on a silica gel column (Hexanes: Acetone = 
6:1) to afford the product 22 (626 mg, 85%) as white powder. [α]D
20 = +12.6 (c 1.0, CH2Cl2). 
1H 
NMR (CDCl3, 400 MHz): δ 7.30-7.63 (m, 26 H), 7.22-7.27 (m, 3 H), 7.16-7.21 (m, 3 H), 6.89-
6.96 (m, 2 H), 5.90 (dd, J = 9.4, 10.65 Hz, 1 H), 5.76 (d, J = 8.3 Hz, 1 H), 5.59 (s, 1 H), 5.29 (t, J 
= 9.7 Hz, 1 H), 5.17 (d, J = 10.6 Hz, 1 H), 4.92-4.99 (m, 2 H), 4.72-4.82 (m, 2 H), 4.63 (t, J = 11.6 
Hz, 1 H), 4.54 (dd, J = 8.3, 10.8 Hz, 1 H), 4.25-4.47 (m, 9 H), 3.93-4.05 (m, 3 H), 3.61-3.73 (m, 2 
H), 3.49-3.60 (m, 3 H),  3.44 (d, J = 11.3 Hz, 1 H), 3.14 (s, 1 H), 2.98-3.04 (m, 1 H), 2.13 (s, 3 H), 
2.12 (s, 3 H), 1.90 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 170.5, 170.2, 169.6, 139.0, 138.7, 138.6, 
138.5, 138.3, 137.6, 134.2, 128.7, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.7, 
127.6, 127.3, 126.9, 126.4, 123.4, 102.4 (2 C), 100.9, 99.3, 83.1, 81.8, 81.3, 76.9, 75.9, 75.8, 75.1, 
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74.8, 74.3, 73.1, 71.9, 71.0, 70.8, 69.0, 68.9, 67.9, 66.4, 62.2, 54.8, 53.7, 20.9, 20.8, 20.5. HRMS: 
[M + Na]+ C74H75NNaO20 calcd for 1320.4780, found 1320.4806. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-
(2-O-benzyl-β-D-galactopyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (23) 
    To a solution of compound 22 (602 mg, 0.46 mmol) in anhydrous MeOH (10 mL) was 
added TsOH (16.0 mg) and EtSH (0.21 mL, 2.93 mmol). The reaction mixture was stirred at rt. 
for 6 hours then quenched with triethylamine and evaporated under reduced pressure. The mixture 
was purified with silica column (Hexanes: Acetone=5:1) to get white power compound 23 (445 
mg, 80%). [α]D
20 = +17.7 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.51-7.66 (m, 4 H), 
7.41-7.45 (m, 2 H), 7.25-7.40 (m, 18 H), 7.06-7.17 (m, 3 H), 6.83 (d, J = 6.7 Hz, 2 H), 5.86 (dd, J 
= 9.1, 10.6 Hz, 1 H), 5.65 (d, J = 8.5 Hz, 1 H), 5.18 (t, J = 9.4 Hz, 1 H), 4.88-4.96 (m, 3 H), 4.69-
4.76 (m, 2 H), 4.62 (d, J = 12.0 Hz, 1 H), 4.43-4.56 (m, 2 H), 4.37-4.41 (m, 1 H), 4.23-4.32 (m, 9 
H), 3.95-4.03 (m, 3 H), 3.87-3.93 (m, 1 H), 3.68-3.75 (m, 1 H), 3.52-3.66 (m, 2 H), 3.38-3.50 (m, 
5 H), 3.23-3.29 (m, 1 H), 3.03-3.08 (m, 1 H), 2.83 (d, J=1.5 Hz, 1 H), 2.15 (s, 3 H), 2.09 (s, 3 H), 
1.88 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 170.8, 170.1, 169.5, 138.8, 138.6, 138.4, 138.3, 134.3, 
128.4 (2 C), 128.3, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7 (2 C), 127.6, 127.5, 126.8, 126.3, 
123.5, 102.4, 102.1, 98.7, 84.3, 82.8, 81.7, 77.8, 76.3, 75.7, 75.0, 74.7, 74.3, 73.9, 73.1, 72.1, 70.9, 
70.5, 69.0, 68.0, 67.7, 62.2, 61.9, 54.6, 20.8, 20.7, 20.4. HRMS: [M + Na]+ C67H71NNaO20 calcd 
for 1232.4467, found 1232.4490. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→3)-
[ 2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)-3, 6-di-O-benzyl-2-deoxy-acetamido-




    Powdered molecular sieves (4 Å) (1.0 g) was added to a solution of Compound 3 (230 
mg, 0.27mmol) and 23 (261 mg, 0.21 mmol) in anhydrous dichloromethane (10 mL). The 
suspension was stirred under nitrogen for 1.5 hours at room temperature and then cooled to -30°C. 
Then NIS (61 mg, 0.27 mmol), and AgOTf (35 mg, 0.105 mmol) was sequentially added to the 
reaction mixture. After stirring for 2 h at -30°C, the mixture was allowed to warm up to rt. 
overnight, diluted with CH2Cl2, filtered through Celite. The filtrate was diluted with CH2Cl2 and 
washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue was 
purified on a silica gel column (Hexanes: Acetone = 5:1) to afford the product 24 (295 mg, 70%) 
as white powder. [α]D
20 = +13.0 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.76-8.08 (m, 5 
H), 7.49-7.72 (m, 3 H), 7.17-7.48 (m, 25 H), 6.96-7.11 (m, 5 H), 6.87-6.95 (m, 3 H), 6.74 (d, J = 
7.3 Hz, 2 H), 5.55-5.61 (dd, J = 9.3, 10.37 Hz, 1 H), 5.30 (d, J = 3.3 Hz, 1 H), 5.11-5.20 (m, 2 H), 
5.04 (d, J = 8.5 Hz, 1 H), 4.69-4.95 (m, 9 H), 4.42-4.66 (m, 6 H), 4.21-4.39 (m, 6 H), 4.03-4.15 
(m, 5 H), 3.91-4.02 (m, 3 H), 3.70-3.88 (m, 4 H), 3.50-3.68 (m, 4 H), 3.23-3.46 (m, 8 H), 3.00-
3.07 (m, 1 H), 2.60-2.69 (m, 1 H), 2.11 (s, 3 H), 2.09 (s, 3 H), 2.08 (s, 3 H), 2.07 (s, 3 H), 2.03 (s, 
3 H), 2.00 (s, 3 H), 1.85 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 171.2, 170.4, 170.3, 170.1, 170.0, 
169.2, 169.2, 138.8, 138.7, 138.5, 138.3, 138.2, 137.7, 137.6, 128.7, 128.5, 128.4, 128.3, 128.2 (2 
C), 128.0 (2 C), 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 126.6, 126.2, 102.5, 101.8, 100.3, 
97.8, 97.4, 84.6, 82.9, 81.8, 77.9 (2 C), 77.3, 76.5, 76.1, 75.7, 75.0, 74.8, 74.7, 74.5, 74.4, 73.7, 
73.1, 71.4, 71.0, 70.9, 70.4, 70.1, 70.0, 69.5, 69.4, 69.2, 67.8, 67.2, 66.9, 65.5, 64.5, 62.2, 60.7, 
55.6, 54.1, 20.9, 20.7, 20.7, 20.6 (3 C), 20.4. HRMS: [M + Na]+ C109H114N2NaO35 calcd for 
2033.7100, found 2033.7129. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl)-(1→3)-[ 2, 




O-benzyl- β-D-glucopyranoside (25) 
    Following the general procedure (A), compound 24 (400 mg, 0.20 mmol) yielded the 
compound 25 (183 mg, 70% over two steps). [α]D
20 = -2.0 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 
MHz): δ 7.16-7.51 (m, 35 H), 5.20-5.36 (m, 2 H), 4.97-5.20 (m, 6 H), 4.89-4.97 (m, 2 H), 4.69-
4.89 (m, 8 H), 4.56-4.69 (m, 4 H), 4.29-4.56 (m, 7 H), 4.08-4.26 (m, 2 H), 3.41-4.04 (m, 20 H), 
3.32-3.40 (m, 1 H), 3.23-3.31 (m, 1 H), 3.08-3.19 (d, J = 8.6 Hz, 1 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 
2.08 (s, 3 H), 2.04 (s, 3 H), 2.01 (s, 3 H), 1.98 (s, 9 H), 1.92 (s, 3 H), 1.57 (s, 3 H); 13C NMR (D2O, 
100 MHz): δ 171.0, 170.9, 170.6 (2 C), 170.2, 170.0, 169.8, 169.7, 169.3 (2 C), 139.1, 139.0, 
138.7, 138.5, 138.2, 137.9, 137.4, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 
127.8, 127.7 (2 C), 127.6, 127.5, 126.6, 102.4, 102.0, 101.1, 100.0, 99.8, 82.9, 82.0, 79.9, 78.4, 
78.2, 77.4, 76.4, 75.5,  75.0, 74.8, 74.1, 73.7, 73.6, 73.3, 72.7, 72.3, 71.7, 71.0, 70.9, 70.4, 69.5, 
68.3, 67.9, 66.9, 66.7, 61.5, 60.8, 55.2, 54.3, 53.9, 20.9, 20.8 (2 C), 20.7 (2 C), 20.6 (3 C), 20.50 
(2 C). HRMS: [M + Na]+ C99H116N2NaO34 calcd for 1899.7307, found 1899.7357. 
    2-deoxy-acetamido-β-D-glucopyranosyl (1→3)-[β-D-galactopyranosyl-(1→4)-2-
deoxy-acetamido-β-D-glucopyranosyl]-(1→6)-β-D-galactopyranosyl-(1→4)-α,β-D-
glucopyranose (HMO3) 
    Following the general procedure (B) and (C), compound 25 (183 mg, 0.098 mmol) 
yielded the compound HMO3 (85 mg, 95%). 1H NMR (D2O, 400 MHz): δ 5.14 (d, J = 3.8 Hz, 
0.54 H, Glc-1 H-1 of α form), 4.54-4.63 (m, overlap with D2O,  2.46 H, GlcNAc-1, GlcNAc-2, H-
1, Glc-1 H-1 of β form), 4.39 (d, J = 7.8 Hz,  Gal-1, 1 H), 4.35 (d, J = 7.8 Hz, Gal-1, 1 H), 4.06 
(d, J = 3.1 Hz, 1 H), 3.82-3.95 (m, 4 H), 3.42-3.82(m, 22 H), 3.33-3.42 (m, 2 H), 3.21 (t, J = 8.39 
Hz, 1 H), 1.98 (s, 3 H), 1.96 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 174.9, 174.5, 103.0, 102.9, 
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102.8 (GlcNAc-1, GlcNAc-2, Gal-2, C-1), 101.0 (Gal-1, C-1), 95.7 (Glc-1, C-1 of β form), 91.8 
(Glc-1, C-1 of α form), 81.7, 79.0, 78.9, 78.4, 75.7, 75.3, 74.7, 74.7, 74.4, 73.9, 73.6, 73.5, 72.5, 
72.4, 71.0, 69.9, 69.7, 68.7, 68.6, 68.4, 61.0, 60.5, 60.0, 55.7, 55.0, 22.4, 22.2. HRMS: [M + Na]+ 
C34H58N2NaO26 calcd for 933.3175, found 933.3161. 
HMO11   
    1H NMR (D2O, 500 MHz): δ 5.10(d, J = 3.5 Hz, 0.61 H, Glc-1 H-1 of α form), 4.50-
4.60 (m, 2.39 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.33-4.37 (m, 2 H, Gal-2 
H-1, Gal-3 H-1 ), 4.31 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.02 (d, J = 3.1 Hz, 1 H), 3.78-3.79 (m, 6 
H), 3.57-3.76 (m, 18 H), 3.53-3.57 (m, 2 H), 3.39-3.51 (m, 7 H), 3.17 (t, J = 8.3 Hz, 1 H), 1.94 (s, 
3 H), 1.91 (s, 3 H). MALDI-MS: [M + Na]+ C40H68N2NaO31 calcd for 1095.370, found 1095.390. 
 
HMO12  
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.5 Hz, 0.51 H, Glc-1 H-1 of α form), 4.50-
4.58 (m, 2.49 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.36 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.03 (d, J = 3.0 Hz, 1 H), 3.38-3.91 (m,  47H), 3.17 (t, J = 8.3 Hz, 1 
H), 2.52-2.57 (m, 2 H), 1.97 (s, 3 H), 1.93 (s, 3 H), 1.91 (s, 6 H), 1.55-1.63 (m, 2 H). ESI-MS: [M 





    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.7 Hz, 0.29 H, Glc-1 H-1 of α form), 4.50-
4.63 (m, 2.71 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.36 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.99 (s, 4 H), 3.38-3.91 (m,  48 H), 3.18 (t, 
J = 8.3 Hz, 1 H), 2.52-2.60 (m, 2 H), 1.97 (s, 3 H), 1.93 (s, 3 H), 1.55-1.65 (m, 2 H). ESI-MS: [M 
– 2H]2- C62H100N4O49 calcd for 842.2734, found 842.2760. 
HMO14  
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.5 Hz, 0.33 H, Glc-1 H-1 of α form), 4.96-
5.02 (m, 2 H, Fuc-1 H-1, Fuc-2 H-1), 4.50-4.61 (m, 2.67 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-
1 H-1 of β form), 4.28-4.36 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.01 (d, J = 3.1 Hz, 1 H), 
3.63-3.91 (m, 25 H), 3.40-3.63 (m, 21 H), 3.35-3.39 (m, 2 H), 3.17 (t, J = 8.4 Hz,  1 H), 1.90-1.93 
(d, J = 6.5 Hz, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd for 1387.487, found 1387.486. 
HMO15   
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    1H NMR (D2O, 500 MHz): δ 5.15-5.22 (m, 2 H, Fuc-1 H-1, Fuc-2 H-1), 5.10(d, J = 3.5 
Hz, 0.33 H, Glc-1 H-1 of α form), 4.45-4.61 (m, 2.67 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-
1 of β form), 4.39-4.45 (m, 2 H, Gal-2 H-1, Gal-3 H-1), 4.30 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.06-
4.13 (m, 2 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.41-3.91 (m, 44 H), 3.30-3.39 (m, 2 H), 3.16 (t, J = 8.4 
Hz,  1 H), 1.93 (s, 3 H), 1.91 (s, 3 H), 1.09-1.11 (d, J = 6.7 Hz, 6 H). MALDI-MS: [M + Na]+ 
C52H88N2NaO39 calcd for 1387.487, found 1387.490. 
 
HMO16  
    1H NMR (D2O, 500 MHz): δ 5.12-5.18(m, 2 H, Fuc-2 H-1, Fuc-4 H-1), 5.10 (d, J = 3.5 
Hz, 0.40 H, Glc-1 H-1 of α form), 4.93-5.01 (m, 2 H, Fuc-1 H-1, Fuc-3 H-1), 4.70-4.78 (m, 2 H), 
4.45-4.61 (m, 2.60 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.35-4.41 (m, 2 H, 
Gal-2 H-1, Gal-3 H-1), 4.31 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.09-4.16 (m, 2 H), 4.00 (d, J = 3.1 
Hz, 1 H), 3.41-3.91 (m, 44 H), 3.28-3.38 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 
3 H), 1.10-1.15 (m, 12 H). MALDI-MS: [M + Na]+ C64H108N2NaO47 calcd for 1679.602, found 
1679.607. 
HMO21  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.22 H, Glc-1 H-1 of α form), 4.45-
4.61 (m, 2.78 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.26-4.36 (m, 2 H, Gal-1 
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H-1, Gal-2 H-1), 4.17-4.22 (m, 1 H), 4.09-4.16 (m, 2 H), 4.00 (d, J = 3.1 Hz, 1 H), 3.36-3.90 (m, 
32 H), 3.26-3.36 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.50-2.56 (m, 1 H), 1.92 (s, 3 H), 1.91 (s, 3 
H), 1.89 (s, 3 H), 1.58 (t, J = 12.3 Hz,  1 H). ESI-MS: [M – H]- C45H74N3O34 calcd for 1200.4159, 
found 1200.4190. 
HMO22  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.27 H, Glc-1 H-1 of α form), 4.47-
4.62 (m, 2.73 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.35 (m, 2 H, Gal-1 
H-1, Gal-2 H-1), 4.06-4.16 (m, 1 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.99 (s, 2 H), 3.38-3.90 (m, 33 H), 
3.29-3.37 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.53-2.58 (m, 1 H), 1.93 (s, 3 H), 1.92 (s, 3 H), 1.60 
(t, J = 12.3 Hz, 1 H). ESI-MS: [M – H]- C45H74N3O35 calcd for 1216.4108, found 1216.4129. 
HMO23  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.36 H, Glc-1 H-1 of α form), 5.00 (d, 
J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.46-4.60 (m, 2.64 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of 
β form), 4.28-4.36 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.02 (d, J = 3.1 Hz, 1 H), 3.40-3.90 (m, 31 H), 
3.29-3.40 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.50-2.56 (m, 1 H), 1.94 (s, 3 H), 1.90 (s, 3 H), 1.05 




    1H NMR (D2O, 500 MHz): δ 5.19 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09 (d, J = 3.6 Hz, 
0.50 H, Glc-1 H-1 of α form), 4.46-4.60 (m, 2.50 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of 
β form), 4.42 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.31 (d, J = 8.0 Hz, 1 H, Gal-1 H-1), 4.07-4.12 (m, 
1 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.41-3.90 (m, 28 H), 3.29-3.38 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 
1.94 (s, 3 H), 1.91 (s, 3 H), 1.10 (d, J = 6.5 Hz, 3 H). MALDI-MS: [M + Na]+ C40H68N2NaO30 
calcd for 1079.376, found 1079.379. 
 
HMO25  
    1H NMR (D2O, 500 MHz): δ 5.09(d, J = 3.9 Hz, 0.28 H, Glc-1 H-1 of α form), 4.48-
4.62 (m, 2.72 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.37 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.01 (d, J = 3.1 Hz, 1 H), 3.38-3.90 (m, 41 H), 3.17 (t, J = 8.4 Hz,  1 
H), 2.50-2.57 (m, 1 H),  1.93 (s, 3 H), 1.92 (s, 3 H), 1.90 (s, 3 H), 1.59 (t, J = 11.9 Hz, 1 H). ESI-





    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.7 Hz, 0.51 H, Glc-1 H-1 of α form), 4.50-
4.63 (m, 2.49 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.37 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 2.9 Hz, 1 H), 3.99 (s, 2 H),  3.39-3.90 (m, 41 H), 3.17 
(t, J = 8.3 Hz,  1 H), 2.54-2.59 (m, 1 H),  1.94 (s, 3 H), 1.93 (s, 3 H), 1.61 (t, J = 12.2 Hz, 1 H). 
ESI-MS: [M – H]- C51H84N3O39 calcd for 1378.4637, found 1378.4660. 
HMO27   
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.7 Hz, 0.55 H, Glc-1 H-1 of α form), 5.00 (d, 
J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.69-4.74 (m, 1 H), 4.50-4.61 (m, 2.45 H, GlcNAc-1 H-1, GlcNAc-
2 H-1, Glc-1 H-1 of β form), 4.28-4.38 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 
2.9 Hz, 1 H), 3.34-3.91 (m, 32 H), 3.17 (t, J = 8.3 Hz,  1 H), 2.54-2.59 (m, 1 H), 1.94 (s, 3 H), 1.90 




     1H NMR (D2O, 500 MHz): δ 5.19 (d, J = 2.4 Hz, 1H, Fuc-1 H-1), 5.10 (d, J = 3.7 Hz, 
0.42 H, Glc-1 H-1 of α form), 4.48-4.60 (m, 2.58 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of 
β form), 4.28-4.45 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.06-4.15 (m, 1 H), 4.01 (d, J = 2.9 
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Hz, 1 H), 3.38-3.90 (m, 31 H), 3.31-3.37 (m, 1 H), 3.17(t, J = 8.8 Hz,  1 H), 1.93 (s, 3 H), 1.91 (s, 
3 H), 1.10 (d, J = 6.5 Hz, 3 H). MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd for 1241.428, found 
1241.423. 
HMO29  
    1H NMR (D2O, 500 MHz): δ 5.15 (d, J = 2.6 Hz, 1 H, Fuc-2 H-1), 5.09(d, J = 3.7 Hz, 
0.36 H, Glc-1 H-1 of α form), 4.99 (d, J = 3.7 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 4.46-4.61 
(m, 2.64 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.42 (d, J = 7.8 Hz, 1 H, Gal-2 
H-1), 4.31 (d, J = 8.0 Hz, 1 H, Gal-1 H-1), 4.10-4.16 (m, 1 H), 4.01 (d, J = 2.9 Hz, 1 H), 3.40-3.92 
(m, 33 H), 3.29-3.37 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.90 (s, 3 H), 1.09-1.16 (m, 
6 H). MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 1225.433, found 1225.438. 
HMO210  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.6 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.5 Hz, 
0.40 H, Glc-1 H-1 of α form), 4.93-5.01 (m, 2 H, Fuc-1 H-1, Fuc-3 H-1), 4.67-4.79 (m, 2 H), 4.45-
4.61 (m, 2.60 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.26-4.41 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.09-4.16 (m, 1 H), 4.00 (d, J = 3.1 Hz, 1 H), 3.41-3.91 (m, 44 H), 
3.28-3.40 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 3 H), 1.02-1.17 (m, 9 H). 




    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.7 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.7 Hz, 
0.47 H, Glc-1 H-1 of α form), 4.99 (d, J = 3.7 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 4.49-4.62 
(m, 2.53 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.41 (m, 3 H, Gal-1 H-1, 
Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.01 (d, J = 3.2 Hz, 1 H), 3.77-3.91 (m, 8 H), 3.39-
3.77 (m, 35 H), 3.30-3.36 (m, 1 H), 3.17 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.90 (s, 3 H), 1.09-
1.16 (m, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd for 1387.486, found 1387.490. 
HMO31   
    1H NMR (D2O, 500 MHz): δ 5.09(d, J = 3.7 Hz, 0.31 H, Glc-1 H-1 of α form), 4.47-
4.58 (m, 2.69 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.34 (m, 2 H, Gal-1 
H-1, Gal-2 H-1), 4.06-4.16 (m, 1 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.28-3.91 (m, 35 H), 3.26-3.36 (m, 
2 H), 3.18 (t, J = 8.4 Hz,  1 H), 2.51-2.57 (m, 1 H), 1.96 (s, 3 H), 1.92 (s, 3 H), 1.91 (s, 3 H), 1.59 
(t, J = 12.2 Hz,  1 H). ESI-MS: [M – H]- C45H74N3O34 calcd for 1200.4159, found 1200.4122. 
HMO32   
     1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.9 Hz, 0.28 H, Glc-1 H-1 of α form), 4.50-
4.58 (m, 2.72 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.34 (m, 2 H, Gal-1 
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H-1, Gal-2 H-1), 4.02 (d, J = 3.2 Hz, 1 H), 3.28-3.91 (m, 35 H), 3.18 (t, J = 8.3 Hz,  1 H), 2.53-
2.58 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 3 H), 1.59 (t, J = 12.2 Hz,  1 H). ESI-MS: [M – H]- C45H74N3O35 
calcd for 1216.4108, found 1216.4139. 
 
HMO33  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.7 Hz, 0.19 H, Glc-1 H-1 of α form), 4.98 (d, 
J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.66-4.73 (m, 1 H), 4.48-4.58 (m, 2.81 H, GlcNAc-1 H-1, GlcNAc-
2 H-1, Glc-1 H-1 of β form), 4.27-4.35 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.02 (d, J = 3.1 Hz, 1 H), 
3.28-3.90 (m, 38 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.92 (s, 3 H), 1.90 (s, 3 H), 1.04 (d, J = 6.6 Hz,  3 
H). MALDI-MS: [M + Na]+ C40H68N2NaO30 calcd for 1079.376, found 1079.380. 
HMO34  
    1H NMR (D2O, 500 MHz): δ 5.18 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09(d, J = 3.9 Hz, 
0.41 H, Glc-1 H-1 of α form), 4.66-4.73 (m, 1 H), 4.45-4.58 (m, 2.59 H, GlcNAc-1 H-1, GlcNAc-
2 H-1, Glc-1 H-1 of β form), 4.39-4.44 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.31 (d, J = 7.5 Hz, 1 H), 
4.06-4.12 (m, 2 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.39-3.90 (m, 28 H), 3.28-3.38 (m, 3 H), 3.16 (t, J = 
8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.11 (d, J = 6.7 Hz, 3 H). MALDI-MS: [M + Na]+ 




    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.53 H, Glc-1 H-1 of α form), 4.51-
4.60 (m, 2.47 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.37 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.38-3.91 (m, 41 H), 3.18 (t, J = 8.4 Hz,  1 
H), 2.50-2.57 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 6 H), 1.59 (t, J = 12.0 Hz,  1 H). ESI-MS: [M – H]- 
C51H84N3O39 calcd for 1362.4687, found 1362.4799. 
HMO36  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.52 H, Glc-1 H-1 of α form), 4.50-
4.60 (m, 2.48 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.38 (m, 3 H, Gal-1 
H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.99 (s, 2 H),  3.38-3.91 (m, 41 H), 3.18 
(t, J = 8.4 Hz,  1 H), 2.53-2.59 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 3 H), 1.59 (t, J = 12.0 Hz,  1 H). 
ESI-MS: [M – H]- C51H84N3O39 calcd for 1378.4637, found 1378.4609. 
HMO37  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.34 H, Glc-1 H-1 of α form), 4.98 (d, 
J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.67-4.74 (m, 1 H), 4.50-4.61 (m, 2.66 H, GlcNAc-1 H-1, GlcNAc-
2 H-1, Glc-1 H-1 of β form), 4.27-4.38 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.01 (d, J = 
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3.1 Hz, 1 H), 3.30-3.90 (m, 37 H), 3.16 (t, J = 8.6 Hz,  1 H), 1.92 (s, 3 H), 1.91 (s, 3 H), 1.05 (d, J 
= 6.6 Hz,  3 H). MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd for 1241.428, found 1241.436. 
HMO38  
    1H NMR (D2O, 500 MHz): δ 5.18 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09 (d, J = 3.8 Hz, 
0.69 H, Glc-1 H-1 of α form), 4.46-4.60 (m, 2.31 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of 
β form), 4.28-4.43 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.07-4.13 (m, 1 H), 4.02 (d, J = 3.2 
Hz, 1 H), 3.39-3.89 (m, 36 H), 3.33-3.38 (m, 1 H), 3.17 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 
3 H), 1.11 (d, J = 6.5 Hz, 3 H). MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd for 1241.428, found 
1241.435. 
HMO39  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.9 Hz, 1 H, Fuc-2 H-1), 5.10(d, J = 3.7 Hz, 
0.39 H, Glc-1 H-1 of α form), 4.97 (d, J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 4.45-4.58 
(m, 2.61 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.40 (m, 2 H, Gal-1 H-1, 
Gal-2 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.06 Hz, 1 H), 3.40-3.93 (m, 33 H), 3.29-3.38 (m, 3 
H), 3.16(t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.91 (s, 3 H), 1.08-1.17 (m, 6 H). MALDI-MS: [M + 




    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 3.0 Hz, 1 H, Fuc-3 H-1), 5.09 (d, J = 3.7 Hz, 
0.62 H, Glc-1 H-1 of α form), 4.96-5.01 (m, 2 H), 4.69-4.78 (m, overlap with D2O, 2 H), 4.47-4.61 
(m, 2.38 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.40 (m, 3 H, Gal-1 H-1, 
Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.2 Hz, 1 H), 3.32-3.93 (m, 43 H), 3.16 (t, 
J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 3 H), 1.02-1.17 (m, 9 H). MALDI-MS: [M + Na]+ 
C58H98N2NaO43 calcd for 1533.544, found 1533.550. 
HMO311  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 3.2 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.6 Hz, 
0.67 H, Glc-1 H-1 of α form), 4.97 (d, J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.72-4.77 (m, 1 H), 4.47-4.60 
(m, 2.37 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.39 (m, 3 H, Gal-1 H-1, 
Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.39-3.93 (m, 41 H), 3.30-
3.38 (m, 1 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.09-1.17 (m, 6 H). MALDI-






MALDI-MS: [M + Na]+ C15H29NNaO11 calcd for 422.1638, found 422.032. 
H0401 
 
MALDI-MS: [M + Na+H2O]






































MALDI-MS: [M + Na]+ C23H42N2NaO16 calcd for 625.2432, found 625.267. 
H0403 
 












































ESI-MS: [M – H]- C26H46N2O20 calcd for 705.2566, found 705.2659. 
H0405 
 
ESI-MS: [M – H]- C26H45N2O19 calcd for 689.2617, found 689.506. 
Yuxi_H0404 #185 RT: 1.36 AV: 1 NL: 1.42E6
T: FTMS - p ESI Full ms [200.00-2000.00]































































































ESI-MS: [M – H]- C26H46N2O20 calcd for 705.2566, found 705.584. 
H0407 
 













































ESI-MS: [M – H]- C37H62N3O27 calcd for 980.3571, found 980.3666. 
YUXI_H0408 #201-336 RT: 1.47-2.46 AV: 136 NL: 2.26E5
T: FTMS - p ESI Full ms [200.00-2000.00]






































































YUXI_H0409 #75 RT: 0.55 AV: 1 NL: 3.52E5
T: FTMS - p ESI Full ms [200.00-2000.00]
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ESI-MS: [M - H]- C32H55N2O24 calcd for 851.3145, found 851.3260. 
H0411 
 
MALDI-MS: [M - H]- C32H55N2O24 calcd for 851.3145, found 851.689. 
Yuxi_H0410 #335 RT: 2.46 AV: 1 NL: 1.96E5
T: FTMS - p ESI Full ms [200.00-2000.00]
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MALDI-MS: [M + Na]+ C18H32NaO16 calcd for 527.1588, found 526.970. 
H0501 
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YUXI_H0501 #332-335 RT: 2.44-2.47 AV: 4 NL: 5.64E5
T: FTMS - p ESI Full ms [200.00-2000.00]













































































MALDI-MS: [M - H]- C29H48NO24 calcd for 794.2566, found 794.664. 
H0503 
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MALDI-MS: [M + Na]+ C32H55NNaO26 calcd for 892.2910, found 892.050. 
H0505 
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MALDI-MS: [M + Na]+ C26H45NNaO21 calcd for 730.2382, found 730.093. 
H0601 
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MALDI-MS: [M + Na]+ C32H55NNaO25 calcd for 876.2961, found 876.279. 
H0603 
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MALDI-MS: [M - H]- C37H61N2O29 calcd for 997.3360, found 997.760. 
H0607 
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YUXI_H0607 #297 RT: 2.20 AV: 1 NL: 3.08E6
T: FTMS - p ESI Full ms [200.00-2000.00]
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MALDI-MS: [M + Na]+ C38H65NNaO29 calcd for 1022.3540, found 1022.510. 
H0609 
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YUXI_H0609 #115-226 RT: 0.84-1.66 AV: 112 NL: 3.55E4
T: FTMS - p ESI Full ms [200.00-2000.00]
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T: FTMS - p ESI Full ms [200.00-2000.00]
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MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd for 1241.4283, found 1241.329. 
H0704 
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MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd for 1241.4283, found 1241.331. 
H0706 
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MALDI-MS: [M + Na]+ C54H91N3NaO41 calcd for 1460.5026, found 1460.903. 
H0801 
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YUXI_H0801 #402 RT: 3.02 AV: 1 NL: 3.33E4
T: FTMS - p ESI Full ms [200.00-2000.00]
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MALDI-MS: [M + Na]+ C34H58N2NaO26 calcd for 933.3175, found 933.365. 
H0901 
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YUXI_H0901 #387 RT: 2.90 AV: 1 NL: 1.67E6
T: FTMS - p ESI Full ms [200.00-2000.00]

















































































ESI-MS: [M - H]- C45H74N3O34 calcd for 1200.4154, found 1201.073 
H0903 
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YUXI_H0903 #367 RT: 2.72 AV: 1 NL: 8.19E4
T: FTMS - p ESI Full ms [200.00-2000.00]
















































































ESI-MS: [M - H]- C51H84N3O39 calcd for 1362.4682, found 1362.4810 
H0905 
 
YUXI_H0904 #348 RT: 2.58 AV: 1 NL: 1.35E6
T: FTMS - p ESI Full ms [200.00-2000.00]































































































MALDI-MS: [M + Na]+ C40H68N2NaO31 calcd for 1095.3704, found 1095.343. 
H0906 
 
MALDI-MS: [M + Na]+ C40H68N2NaO30 calcd for 1079.3755, found 1079.226. 
H0907 
 



















































ESI-MS: [M – 2H]2- C62H100N4O47 calcd for 826.2784, found 826.2866. 
H0909 
 
ESI-MS: [M – 2H]2- C62H100N4O47 calcd for 826.2784, found 826.2863. 
YUXI_H0908 #307 RT: 2.27 AV: 1 NL: 4.11E5
T: FTMS - p ESI Full ms [200.00-2000.00]





































































YUXI_H0909 #86 RT: 0.63 AV: 1 NL: 8.62E4
T: FTMS - p ESI Full ms [200.00-2000.00]






















































































MALDI-MS: [M + Na]+ C54H91N3NaO40 calcd for 1444.5077, found 1444.307. 
H0911 
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T: FTMS - p ESI Full ms [200.00-2000.00]



















































































MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 1225.433, found 1225.396. 
H0915 
 





































MALDI-MS: [M + Na]+ C26H45NNaO21 calcd for 730.2382, found 729.946. 
H1001 
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MALDI-MS: [M + Na]+ C32H55NNaO25 calcd for 876.2961, found 876.007. 
H1005 
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ESI-MS: [M - H]- C43H71N2O33 calcd for 1143.3939, found 1143.4055 
H1007 
 
MALDI-MS: [M - H]- C43H71N2O33 calcd for 1143.3939, found 1144.214 
YUXI_H1006 #681 RT: 4.99 AV: 1 NL: 4.17E5
T: FTMS - p ESI Full ms [200.00-2000.00]
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MALDI-MS: [M + 2Na - H]+ C14H24NNa2O11 calcd for 428.1145, found 428.146. 
H1101 
 

















































ESI-MS: [M - H]- C36H58N3O27 calcd for 964.3258, found 964.3356 
Yuxi_H1102_190222170405 #417 RT: 3.18 AV: 1 NL: 9.99E4
T: FTMS - p ESI Full ms [200.00-2000.00]












































































YUXI_H1103 #321 RT: 2.35 AV: 1 NL: 1.13E6
T: FTMS - p ESI Full ms [200.00-2000.00]









































































MALDI-MS: [M + Na]+ C14H24NNaO11 calcd for 406.1325, found 406.129. 
H1201 
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4 ENZYMATIC SYNTHESIS OF O-ANTIGEN FROM P. AERUGINOSA SEROTYPE 
O11 
4.1 Introduction 
Lipopolysaccharides (LPS) are large molecules consisting of a lipid and 
a polysaccharide which contains O-antigen, outer core and inner core. They are found in 
the outer membrane of Gram-negative bacteria. These polysaccharides serve as an important 
molecular which mediate interaction between host cell and surrounding bacterium. Bacterial 
polysaccharides are extremely diverse, and their structural variation results in different serotypes 
or serogroups. For example, over 180 O-PS structures and 60 CPS structures have been 
identified for Escherichia coli. These high diversified LPS protect bacteria from immune 
clearance and act as the major virulence factor. 99 LPS are outstanding vaccine candidate for 
preventing bacterial infection.100-102  There are several bacterial PS based vaccine which are 
commercially available. For example, Pfizer’s PSs conjugate vaccine (PCV) Prevnar contains 
CPSs from 7 serotypes of S. pneumoniae conjugated with a protein, and its newer version 
Prevnar 13 contains protein-conjugated CPSs from 13 serotypes. These two vaccines represent 
Pfizer’s top selling drugs, with an annual revenue of over 6 billion USD. Another example is 
Merk’s 23-valent Pneumococcal PSs vaccine (PPSV), which contains solely PSs from 23 
serotype of S. pneumoniae strains. 103-104 Pseudomonas aeruginosa is one representative of gram 
negative, rod-shape bacterium which is widely distributed in the environment. It is an 
opportunistic pathogen which can cause disease in patient with burn, cut wound or cystic fibrosis 
in the hospital. Treatment for Infections of P. aeruginosa is lacking efficient antibiotic due to its 
resistance to many medicines. Currently Doctor uses a combination antibiotic treatment that 
contains cefepime, aztreonam, ciprofloxacin, levofloxacin, aminoglycosides, ticarcillin and 
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ceftazidime with considerations about how sever of the infection in the patient. The hospitalized 
patients are the major infected people due to their long present in hospital and weakness of 
immune system of body. Infections of P. aeruginosa causing a total of 51000 healthcare 
infections in the USA annually.105-108  
Lipopolysaccharides (LPS) as a major component of the outer membrane of P. aeruginosa is 
composed of variable length of polysaccharides (O-antigen), fat acid chains (lipid A) and 
conservative inner and outer core oligosaccharides. 109 Lipid A usually contains 6 fat acid chains 
or more which are the most challenging part in vitro synthesis because of its highly 
hydrophobicity and complexity. Core oligosaccharides are attached to the lipid A. they are 
comprised of 3-deoxy-D-mannooctulosonic acid (KDO), modified KDO with phosphate, D-
glucose, D-mannose, D-galactose. More than 20 heterogenous serotype of O-antigens of P. 
aeruginosa are the most variable component which leads to different immunological reactivity.  
LPS-Conjugated vaccines are the most widely characterized and studied research field 
because of its accessibility and efficient immunogenicity. P. aeruginosa strain was classified into 
20 major serotypes, O1 to O20, by The International Antigenic Typing Scheme (IATS)110 
Table 4.1 O-Antigen repeat units of the IATS reference strains 
Serotype O-antigen repeat unit 
O1 4-D-GalNAc--D-GlcNAc3NAcA-D-3-D-FucANc-3-QuiNAc 
O2 4- -D-ManNAc3NAmA-4-L-GulNAc3NAcA- -D-FucNAc 
O3 2-L-Rha3OAc-6-D-GlcNAc-4-L-FucNAc--D-QuiNAc4NSHb 
O4 2-L-Rha-3-L-FucNAc-3-L-FucNAc-3-D-QuiNAc 












O15 2- -D-Ribf-4-D-GalNAc 
O16 4--D-ManNAc3NAmA-4-D-ManNAc3NAcA- 3-D-FucNAc 
O17 4- -D-Ribf-4-D-GalNAc 
O18 4-L-GulNAc3NAmA-4-D-ManNAc3NAcA- 3-D-FucNAc 
O19 3-L-Rha-4-L-GalNAcA-3-D-QuiNAc 
O20 4-L-GulNAc3NAmA-4-D-ManNAc3NAcA- 3-D-FucNAc4OAc 
 
O-Antigen from P. aeruginosa serotype O11 is ideal starting target for biosynthesis 
because of its simplicity of oligosaccharide structure. (Figure 4.1) Successful synthesis O-
antigen can be a fundamental stone to develop vaccine to protect human from this specific type 
of P. aeruginosa. Currently the polysaccharides are isolated from bacteria culture as 
heterogeneous mixtures. Access to the pure and homogenous forms of LPS is tremendous benefit 
to such research field. In this study we will address this problem by employing and developing 
step wise chemoenzymatic approaches to get uniform pure O-Antigen.  
 
 
Figure 4.1 P. aeruginosa serotype O11 O-Antigen 
 
4.2 Results and Discussion 
4.2.1 Enzymatic preparation of UDP-L-FucNAc and UDP-ManNAcA 
O-Antigen is synthesized on the inner membrane of cytoplasmic surface. Biosynthesis of 


































developed a highly efficient one-pot multienzyme (OPME) system for hundred milligram scale 
production of sugar nucleotide. We successfully utilized this theory into biosynthesis of UDP-L-
FucNAc and UDP-ManNAcA by taking advantage of sugar nucleotide salvage pathway to avoid 
time-consuming, tedious purification step. 111 
 
Figure 4.2 Biosynthesis of UDP-L-FucNAc 
WbjB and WbjC were cultured at 37°C for overnight. After that inductions were 
activated by adding a low concentration of IPTG (0.2mM) at low temperature 16 °C. Ni-NTA 
affinity chromatography were employed to purify both enzymes with 6His tag to 90% with high 
yield. The estimate yield of both pure WbjB and WbjC from 1L culture is around 10 mg. 
UDP-L-FucNAc was enzymatically synthesized by converting substrate UDP-GlcNAc 
which is more common sugar nucleotide. In our lab we have already addressed problem about 
large scale enzymatic synthesis of common UDP-sugar such as UDP-GlcNAc, UDP-GalNAc, 
UDP-GlcA, UDP-GalA, GDP-Fuc and CMP-Sia.112  UDP-GlcNAc was sequentially epimerized 
by WbjB, WbjC and WbjD. Due to highly instability of UDP-L-FucNAc, the precursor UDP-
PneNAc was enzymatically synthesized with NADPH as a reductant in hundred milligram scale. 
WbjD and Corresponding Glycotransferase WbjE will be added together to get L-FucNAc 
transferred without purification of unstable UDP-L-FucNAc.  
 
Figure 4.3 Biosynthesis of UDP-ManNAcA  
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UDP-ManNAcA was stepwise enzymatical synthesized by Cap5P, an epimerase to flip 
up NHAc group on C2 position, and Cap5O, oxidize C6 with NAD+. Cap5P and Cap5O were 
purified following the abovementioned method. 113 Given the stability of UDP-ManNAcA, 
hundred milligram scale production was achieved in the presence of Mn2+ and NAD+. The Total 
Yield of UDP-ManNAcA atfter P2 purification can reach to 80%. 
4.2.2 Enzymatic Extension of DFucNAc-PP-C11-phenol 
Facile chemoenzymatic synthesis of O-repeat unit-PP-Lipid is the starting point to access 
the production of P. aeruginosa serotype O11 vaccine. In order to biosynthesize this compound 
first monosaccharide-PP-lipid, corresponding sugar nucleotide and Glycotransferase are three 
requirements.  In this manuscript we propose a substrate, monosaccharide-PP-C11-phenol, which 
can be recognized by first glycotransferase WbjE.  
Natural undecaprenol C55 would be the best lipid part candidate which is involved into 
the bacterial polysaccharide synthesis pathway. However due to the low water solubility of lipid 
and extremely difficulty in synthesis. We can start with truncated C11 chain which shows 
relatively high activity towards several steps of glycosylation. In fact, first monosaccharide with 
two phosphate and lipid are the minimum requirement for the formation of first glycosidic bond 
on first sugar.  
In the biosynthesis of LPS from P. aeruginosa, we first transfer UDP-L-PneNAc 
prepared by WbjB, WbjC to DFucNAc-PP-C11-phenol with configuration α1-3. One pot mutil-
enzyme strategy (WbjD and WbjE) was applied to first glycosylation step due to instability of 
UDP-L-FucNAc. Chemical coupling a phenol group to lipid part enable us to overcome the lack 
of UV or florescent detection. This advantage will greatly facilitate us when we purify the 
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bacterial Polysaccharide by HPLC. The next glycosylation step is transferring Glucose to 
LFucANc by WbjA with β1-3 linkage.  
Each step will be monitored by HPLC and Mass spectrum in negative mode, after 80% 
conversion rate, next step will start. C18 was used for separation based on hydrophobicity of 
lipid and phenol monitored by 280 nm UV detector under a gradient condition (solution A: 
water, solution B: acetonitrile; flow rate: 1ml/min B%: 10%-40% within 30min). 
In the future Wzy, a bacterial PS polymerase, and Wzz, a polymerase regulator, both will 
work on the polymerization of O repeat unit of RU-PP-lipid which may shows better 
immunogenicity towards P. aeruginosa serotype O11.   
  




WbjD and WbJE and WbjA were induced at low temperature 16 °C and low 
concentration of IPTG (0.2mM) to get entirely soluble form of enzymes.  
As shown in Figure 27, B is before the IPTG induce, A is after IPTG induce, FT is flow 
through after Ni-NTA affinity column. All these enzymes with 6 his tags were purified as shown 
in the SDS gel. 
 
Figure 5 SDS-PAGE analysis of purified WbjD, WbjE and WbjA 
 
4.3 Conclusion 
Investigation into biosynthesis of O-antigen from P. aeruginosa is an excellent direction 
for synthesis of such macromolecule comparing to chemical method. Enzymatic synthesis 
method shows big advantages of less step, highly specificity toward substrate, easy purification 
and high yield. In the last decade many publications of the O-antigen cluster sequence and 
detailed information about LPS structures enable researcher to advance the real biosynthesis of 
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different type of O-antigen. Here we report that O-antigen DGlc3LFucNAc3DFucNAc-PP-
C11-Phenol was synthesized via WbjE and WbjA. This ongoing project will be further finished 
by synthesizing enough amount of final compound to get NMR result. The biosynthetic O-
Antigen from P. aeruginosa serotype O11 could be valuable structure to be studied as potential 
candidate for an anti P. aeruginosa vaccine. However single repeat unit may not enough to 
activate strong immunogenicity. Longer repeat unit of O-antigen is needed for eliciting 
antibodies. 114 
4.4 Experimental Section 
4.4.1 Materials 
All Chemical reagents were purchased from sigma unless otherwise noted. Ni-NTA 
agarose was purchased from Qiagen. UDP-GlcNAc was prepared by utilizing salvage pathway 
via two enzymes (NahK and AGX1). 115 WbjB, WbjC, WbjD, Cap5P, Cap5O, WbjE and WbjA 
expression E. Coli strain were obtain by collaborating with Dr. Goldberg Joanna’s lab from 
Emory University. 
4.4.2 Expression, and purification of Enzymes 
E. coli cells harboring the recombinant plasmids were grown in high salt LB medium at 
37°C with 20 rpm shaking until OD600 reached 0.6-0.8, followed by addition of isopropyl--D-
thiogalactopyranoside (IPTG) to a final concentration of 0.2mM. The cells were harvested by 
centrifugation at 4000 rpm after 20h induction at 16°C and stored at -20°C until used. A Ni-NTA 
resin (Qiagen) column was utilized to purify desire the proteins by following the manufacture 
instructions. The purified proteins were desalted by PD-10 column (GE life science, USA) 




4.4.3 One pot multi-enzyme synthesis of UDP-PneNAc, UDP-ManNAcA and 
trisaccharide-PP-C11-Phenol 
Production of large scale of UDP- PneNAc and UDP-ManNAcA were performed in a 10 
ml reaction system containing 50mM PH8.0 Tris HCl buffer, 20mM UDP-GlcNAc, 20mM 
MnCl2, 40mM NADPH for UDP-PneNAc, 20mM NAD+ for UDP-ManNAcA and 
corresponding enzymes. The reaction systems were incubated at 37°C water bath for overnight. 
The generation of UDP-PneNAc and UDP-ManNAcA were monitored by TLC (Isopropanol: 
NH4OH: H2O=7:3:2) and Capillary electrophoresis (20mM sodium tetraborate, 254nm, 20min 
and 75um diameter of capillary) and confirmed by MALDI-MS. After converting rate reach to 
80%, the reactions were quenched by boiling for 10 min, centrifuged to remove precipitants and 
concentrated for separation. After that the concentrated reaction system were loading to a gel 
filtration column (Bio-Gel P2, Bio-Rad), fractions containing UDP-PneNAc or UDP-ManNAcA 
were pooled and lyophilized. Glc-3-LFucANc-3-DFucNAc-PP-C11-Phenol was sequentially 
enzymatic synthesized by adding WbjE and WbjA. UDP-L-FucNAc was transferred to 
DFucNAc in a 2ml reaction system containing 50mM PH8.0 Tris HCl buffer, 20mM UDP-
PneNAc, 20mM MnCl2, 20mM substrate and WbjD and WbjE. UDP-Glc was transferred to 
LFucNAc in a 2ml reaction system containing 50mM PH8.0 Tris HCl buffer, 20mM UDP-Glc, 
20mM MnCl2, 20mM substrate and WbjA. the reaction mixture was quenched by boiling for 10 









ESI-MS: [M - H]- C17H24N3O18P2 calcd for 620.05, found 620.0536. 
19-21 #31-67 RT: 0.65-1.44 AV: 37 NL: 1.88E5
T: FTMS - p ESI Full ms [100.00-2000.00]






















































MALDI-MS: [M - H]- C33H55N2O16P2 calcd for 797.31, found 798.376. 
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4.4.4 HPLC method for purification of O-antigen 
Gel filtration was first used for brief purification and desalting of O-antigen. But the final 
compound is still not pure enough to run NMR. Therefore disaccharide-PP-C11-Phenol reaction 
mixture was separated by high performance liquid chromatography (HPLC) and Detected by UV 
detector at 280 nm. Solvent A: 30mM potassium phosphate, PH 6.0; 5mM 
tetrabutylammoniumhydrogen sulfate, 2% acetonitrile and solvent B: acetonitrile was used as 
mobile phase. Xbridge peptide BEH C18 250*4mm (waters) was used as stationary phase. 
Sample was injected into HPLC and eluted by a gradient of solvent B (20%-70%).  
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